C103_contig_851_4	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	46.8	79	90	231	2.85e-23	87.8
C103_contig_851_4	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	54.7	75	90	231	8.62e-22	84.0
C103_contig_851_4	CARD|gb|AAG05188.1|ARO:3005068|ParR	45.3	75	90	235	2.60e-14	64.3
C103_contig_851_6	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	40.4	225	231	231	1.11e-57	181
C103_contig_851_6	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	37.6	229	231	231	3.16e-57	180
C103_contig_851_6	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	35.8	229	231	229	5.96e-57	179
C103_contig_851_6	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	36.4	228	231	231	8.96e-57	179
C103_contig_851_6	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	37.6	229	231	233	9.51e-57	179
C103_contig_851_6	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	36.4	228	231	231	2.54e-56	178
C103_contig_851_6	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	36.4	228	231	231	1.02e-55	176
C103_contig_851_6	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	37.4	230	231	230	1.40e-55	176
C103_contig_851_6	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	36.4	228	231	231	1.44e-55	176
C103_contig_851_6	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	37.2	231	231	231	4.63e-54	172
C103_contig_851_7	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	29.0	262	306	359	1.11e-30	117
C103_contig_851_7	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	30.4	247	306	364	2.23e-28	111
C103_contig_851_7	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	30.4	247	306	364	2.23e-28	111
C103_contig_851_7	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	28.7	230	306	367	5.69e-26	104
C103_contig_851_7	NCBI|WP_021418927.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	28.7	230	306	368	5.76e-26	104
C103_contig_851_7	megares|MEG_7501|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	27.9	247	306	354	2.39e-25	102
C103_contig_851_7	NCBI|AXB64455.1|1|1|vanS-Cd|vanS-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|VanG-Cd-type_glycopeptide_resistance_histidine_kinase_VanS|AMR|glycopeptide	26.8	231	306	380	2.41e-25	103
C103_contig_851_7	megares|MEG_7498|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	26.8	231	306	380	2.41e-25	103
C103_contig_851_7	NCBI|WP_063856734.1|1|1|vanS-E|vanS-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-E|AMR|glycopeptide	27.9	233	306	357	3.44e-25	102
C103_contig_851_7	megares|MEG_7511|Drugs|Glycopeptide|VanE-type_regulator|VANSE_1	27.9	233	306	357	3.44e-25	102
C103_contig_851_8	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	71.2	306	309	307	6.11e-154	432
C103_contig_851_8	SARG|gi|445996710|ref|WP_000074565.1|	53.8	301	309	309	1.21e-103	304
C103_contig_851_8	SARG|gi|445996719|ref|WP_000074574.1|	53.5	301	309	309	1.72e-103	304
C103_contig_851_8	SARG|gi|445996708|ref|WP_000074563.1|	53.5	301	309	309	1.72e-103	304
C103_contig_851_8	SARG|gi|542061059|gb|ERI11611.1|	53.2	299	309	316	2.17e-103	304
C103_contig_851_8	SARG|YP_001373621	52.8	299	309	318	2.32e-103	304
C103_contig_851_8	SARG|gi|895808656|emb|COR83787.1|	53.5	301	309	309	3.46e-103	303
C103_contig_851_8	SARG|gi|445996729|ref|WP_000074584.1|	53.5	301	309	309	4.90e-103	303
C103_contig_851_8	SARG|gi|814314593|emb|CKF49145.1|	53.8	301	309	309	4.90e-103	303
C103_contig_851_8	SARG|gi|895736250|emb|COF64653.1|	53.5	301	309	309	6.94e-103	302
C103_contig_851_12	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	37.7	122	140	231	6.64e-22	86.3
C103_contig_851_12	CARD|gb|AAG05188.1|ARO:3005068|ParR	34.0	97	140	235	2.44e-11	58.2
C103_contig_851_13	SARG|gb|ACJ63262.1|ARO:3003107|mefB	41.1	146	169	409	2.49e-29	110
C103_contig_851_14	megares|MEG_3799|Drugs|beta-lactam|Penicillin_binding_protein|MECC_1	35.9	474	539	664	3.04e-92	295
C103_contig_851_14	megares|MEG_3800|Drugs|beta-lactam|Penicillin_binding_protein|MECC_1	36.4	475	539	665	1.20e-91	293
C103_contig_851_14	SARG|gb|CCC86795.1|ARO:3001209|mecC	35.0	474	539	665	1.69e-91	293
C103_contig_851_14	NCBI|WP_128268231.1|1|1|mecC2|mecC2|insensitivity|2|METHICILLIN|beta-lactam|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecC2|AMR|beta-lactam	35.4	474	539	665	1.69e-91	293
C103_contig_851_14	NCBI|WP_069996660.1|1|1|mecC3|mecC3|insensitivity|2|METHICILLIN|beta-lactam|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecC3|AMR|beta-lactam	35.4	474	539	665	2.37e-91	292
C103_contig_851_14	NCBI|WP_063852700.1|1|1|mecA2|mecA2|insensitivity|2|METHICILLIN|beta-lactam|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecA2|AMR|beta-lactam	33.8	509	539	668	7.91e-89	286
C103_contig_851_14	NCBI|WP_063852694.1|1|1|mecA2|mecA2|insensitivity|2|METHICILLIN|beta-lactam|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecA2|AMR|beta-lactam	33.6	509	539	668	1.64e-87	282
C103_contig_851_14	SARG|KC243783.1.gene1.p01	34.7	487	539	668	1.74e-86	280
C103_contig_851_14	SARG|gi|686116460|ref|WP_031766030.1|	34.7	487	539	668	2.43e-86	279
C103_contig_851_14	megares|MEG_3794|Drugs|beta-lactam|Penicillin_binding_protein|MECA_1	34.5	487	539	668	2.43e-86	279
C103_contig_851_15	SARG|gb|AQX82857.1|ARO:3004185|mecD	38.6	158	166	678	5.30e-28	107
C103_contig_851_15	megares|MEG_3781|Drugs|beta-lactam|Penicillin_binding_protein|MECA_1	38.0	166	166	242	1.23e-27	102
C103_contig_851_15	SARG|gi|686392252|ref|WP_031906577.1|	38.6	166	166	668	1.34e-27	106
C103_contig_851_15	NCBI|WP_063852710.1|1|1|mecB|mecB|insensitivity|2|METHICILLIN|beta-lactam|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecB|AMR|beta-lactam	39.9	163	166	674	2.49e-27	105
C103_contig_851_15	SARG|CAA74376	38.6	166	166	668	8.59e-27	104
C103_contig_851_15	SARG|gi|686288520|ref|WP_031860875.1|	38.0	166	166	668	8.59e-27	104
C103_contig_851_15	SARG|gi|727740855|ref|WP_033857946.1|	38.6	166	166	668	1.17e-26	103
C103_contig_851_15	SARG|gb|BAI83385.1|ARO:3003440|mecB	39.3	163	166	674	1.17e-26	103
C103_contig_851_15	SARG|gi|909708119|ref|WP_049951317.1|	38.0	166	166	649	1.58e-26	103
C103_contig_851_15	SARG|CAA73547	38.0	166	166	668	1.60e-26	103
C103_contig_851_18	CARD|gb|ABU39979.1|ARO:3000217|blaR1	34.9	596	599	588	1.03e-111	345
C103_contig_851_18	NCBI|WP_012705551.1|1|1|blaR1_gen|blaR1_gen|regulation|2|beta-lactam|beta-lactam|BlaR1_family_beta-lactam_sensor/signal_transducer|AMR|beta-lactam	32.3	606	599	593	1.45e-101	319
C103_contig_851_18	megares|MEG_3786|Drugs|beta-lactam|Penicillin_binding_protein|MECA_1	29.7	525	599	585	5.08e-85	275
C103_contig_851_18	NCBI|WP_000952923.1|1|1|mecR1|mecR1|regulation|2|METHICILLIN|beta-lactam|beta-lactam_sensor/signal_transducer_MecR1|AMR|beta-lactam	29.7	525	599	585	5.08e-85	275
C103_contig_851_18	NCBI|WP_001096392.1|1|1|blaR1|blaR1|regulation|2|beta-lactam|beta-lactam|beta-lactam_sensor/signal_transducer_BlaR1|AMR|beta-lactam	32.2	603	599	585	7.52e-84	272
C103_contig_851_18	NCBI|WP_001096386.1|1|1|blaR1-2|blaR1-2|regulation|2|beta-lactam|beta-lactam|beta-lactam_sensor/signal_transducer_BlaR1|AMR|beta-lactam	31.9	605	599	585	7.93e-83	270
C103_contig_851_18	NCBI|WP_063842869.1|1|1|blaR1|blaR1|regulation|2|beta-lactam|beta-lactam|beta-lactam_sensor/signal_transducer_BlaR1|AMR|beta-lactam	30.9	602	599	585	1.23e-80	264
C103_contig_851_18	NCBI|WP_001096376.1|1|1|blaR1|blaR1|regulation|2|beta-lactam|beta-lactam|beta-lactam_sensor/signal_transducer_BlaR1|AMR|beta-lactam	30.9	602	599	585	1.72e-80	263
C103_contig_851_18	SARG|gb|EIM09515.1|ARO:3004747|BAT-1	35.0	254	599	268	1.01e-45	161
C103_contig_851_18	NCBI|WP_075071939.1|1|1|blaOXA-1089|blaOXA-1089_fam|hydrolase|2|CARBAPENEM|beta-lactam|carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-1089|AMR|beta-lactam	38.7	222	599	289	4.60e-44	157
C103_contig_851_19	megares|MEG_1289|Drugs|beta-lactam|Penicillin_binding_protein_regulator|BLAI_1	39.3	117	125	126	2.67e-28	99.4
C103_contig_851_20	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	38.1	97	138	231	5.32e-19	78.6
C103_contig_851_20	CARD|gb|AAG05188.1|ARO:3005068|ParR	31.3	99	138	235	1.71e-12	61.2
C103_contig_851_33	SARG|gb|AAV85982.1|ARO:3000535|macB	31.6	234	265	644	1.84e-21	92.4
C103_contig_851_33	SARG|gi|764278838|ref|WP_044327089.1|	29.4	269	265	648	2.08e-20	89.4
C103_contig_851_33	SARG|gi|754927849|ref|WP_042284850.1|	29.9	234	265	648	5.16e-20	88.2
C103_contig_851_33	SARG|gi|992390012|ref|WP_061077002.1|	29.5	234	265	648	6.98e-20	87.8
C103_contig_851_33	SARG|gi|763407609|ref|WP_044264203.1|	29.0	269	265	648	6.98e-20	87.8
C103_contig_851_33	SARG|gi|757782629|ref|WP_043001213.1|	29.5	234	265	648	1.28e-19	87.0
C103_contig_851_33	SARG|gi|968563772|ref|WP_058587854.1|	29.5	234	265	648	1.73e-19	86.7
C103_contig_851_33	SARG|gi|696411918|ref|WP_032982657.1|	29.4	235	265	647	3.16e-19	85.9
C103_contig_851_33	SARG|gi|696402390|ref|WP_032974230.1|	29.4	235	265	647	3.16e-19	85.9
C103_contig_851_33	SARG|gi|696423952|ref|WP_032993748.1|	29.4	235	265	647	3.16e-19	85.9
C103_contig_851_47	SARG|EU408354.1.gene5.p01	27.5	149	210	294	5.00e-06	45.1
C103_contig_851_54	SARG|gi|749017716|ref|WP_040076354.1|	53.7	218	224	646	7.51e-76	239
C103_contig_851_54	SARG|gi|498115003|ref|WP_010429159.1|	53.7	218	224	646	7.51e-76	239
C103_contig_851_54	SARG|gi|983405167|ref|WP_060572706.1|	53.7	218	224	646	1.05e-75	239
C103_contig_851_54	SARG|gi|782756348|ref|WP_045630015.1|	54.1	218	224	646	1.48e-75	239
C103_contig_851_54	SARG|gi|851922185|ref|WP_048218206.1|	52.8	218	224	648	1.54e-75	239
C103_contig_851_54	SARG|gi|949718947|ref|WP_057063453.1|	52.8	218	224	648	1.54e-75	239
C103_contig_851_54	SARG|gi|696375069|ref|WP_032949617.1|	52.8	218	224	648	1.54e-75	239
C103_contig_851_54	SARG|gi|489127020|ref|WP_003036815.1|	52.8	218	224	648	1.54e-75	239
C103_contig_851_54	SARG|gi|754493745|ref|WP_041910640.1|	53.7	218	224	646	2.07e-75	238
C103_contig_851_54	SARG|gi|779958642|ref|WP_045406003.1|	53.7	218	224	646	2.91e-75	238
C103_contig_851_56	SARG|gb|AAV85982.1|ARO:3000535|macB	32.7	422	424	644	2.60e-50	179
C103_contig_851_56	SARG|gi|736472622|ref|WP_034494292.1|	32.5	428	424	648	1.61e-39	149
C103_contig_851_56	SARG|gi|1001720867|ref|WP_061274204.1|	31.1	428	424	648	2.65e-38	145
C103_contig_851_56	SARG|gi|1035706844|ref|WP_064548272.1|	32.4	429	424	648	4.94e-38	144
C103_contig_851_56	SARG|gi|1035670474|ref|WP_064517458.1|	31.8	428	424	648	9.18e-38	144
C103_contig_851_56	SARG|gi|1035717981|ref|WP_064557480.1|	31.8	428	424	648	9.18e-38	144
C103_contig_851_56	SARG|gi|495736522|ref|WP_008461101.1|	30.8	428	424	648	4.32e-37	142
C103_contig_851_56	SARG|gi|746243059|ref|WP_039291473.1|	30.8	428	424	648	4.32e-37	142
C103_contig_851_56	SARG|gi|746253210|ref|WP_039301529.1|	30.8	428	424	648	4.32e-37	142
C103_contig_851_56	SARG|YP_001438541	30.4	428	424	647	5.85e-37	141
C103_contig_851_58	CARD|gb|BAB38260.1|ARO:3000830|cpxA	29.6	233	434	457	9.28e-20	90.1
C103_contig_851_58	NCBI|WP_063856734.1|1|1|vanS-E|vanS-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-E|AMR|glycopeptide	22.8	215	434	357	3.53e-15	75.5
C103_contig_851_58	megares|MEG_7511|Drugs|Glycopeptide|VanE-type_regulator|VANSE_1	22.8	215	434	357	3.53e-15	75.5
C103_contig_851_59	CARD|gb|ATC67679.1|ARO:3000838|arlR	41.6	219	226	219	1.10e-53	171
C103_contig_851_59	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	34.7	222	226	220	1.91e-43	144
C103_contig_851_59	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	33.8	222	226	219	5.24e-43	143
C103_contig_851_59	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	33.8	222	226	219	7.39e-43	143
C103_contig_851_59	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	33.8	222	226	220	7.60e-43	143
C103_contig_851_59	CARD|gb|AAG06465.1|ARO:3005063|cprR	35.6	222	226	223	8.27e-43	143
C103_contig_851_59	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	33.8	222	226	220	2.14e-42	142
C103_contig_851_59	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	35.0	220	226	228	2.35e-40	137
C103_contig_851_59	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	35.1	225	226	231	1.18e-34	122
C103_contig_851_59	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	30.3	228	226	231	7.13e-33	117
C103_contig_851_66	SARG|gb|AET10445.1|ARO:3004033|tetB(46)	29.8	218	627	578	8.74e-23	101
C103_contig_851_66	SARG|gi|1031496106|ref|WP_064100483.1|	23.9	176	627	492	3.35e-06	48.9
C103_contig_851_66	SARG|gi|517204321|ref|WP_018393139.1|	25.1	175	627	492	4.42e-06	48.5
C103_contig_851_66	SARG|gi|506326044|ref|WP_015845803.1|	23.2	181	627	492	4.42e-06	48.5
C103_contig_851_66	SARG|AJ579365.gene.p01	25.0	180	627	492	5.83e-06	48.1
C103_contig_851_67	SARG|gb|CDO61516.1|ARO:3003949|efrB	35.9	195	622	362	3.10e-30	121
C103_contig_851_67	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	22.0	576	622	574	8.75e-25	107
C103_contig_851_67	NCBI|WP_011116970.1|1|1|tetAB_B|tetAB_B|efflux|2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_TetAB_subunit_B|AMR|tetracycline	27.7	173	622	528	1.05e-12	69.7
C103_contig_851_67	SARG|gb|AVI44920.1|ARO:3004470|poxtA	25.0	196	622	542	9.33e-11	63.5
C103_contig_851_67	NCBI|WP_209691075.1|1|1|poxtA2|poxtA|target_protection|2|CHLORAMPHENICOL/FLORFENICOL/LINEZOLID|OXAZOLIDINONE/PHENICOL|ABC-F_type_ribosomal_protection_protein_PoxtA2|AMR|multidrug	25.0	196	622	544	9.36e-11	63.5
C103_contig_851_67	ResF|poxtA-Ef_1_WP094899500.1_1	26.2	195	622	538	2.82e-10	62.0
C103_contig_851_67	megares|MEG_8639|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|POXT_1	26.2	195	622	543	2.84e-10	62.0
C103_contig_851_67	NCBI|WP_094899500.1|1|1|poxtA-Ef|poxtA-Ef|target_protection|2|CHLORAMPHENICOL/FLORFENICOL/LINEZOLID|OXAZOLIDINONE/PHENICOL|ABC-F_type_ribosomal_protection_protein_PoxtA-Ef|AMR|multidrug	26.2	195	622	543	2.84e-10	62.0
C103_contig_851_67	SARG|U82085.gene.p01	23.6	191	622	552	2.68e-06	49.3
C103_contig_851_73	SARG|P42332	26.5	302	300	306	3.77e-25	101
C103_contig_851_73	SARG|ZP_04081918	27.1	303	300	306	3.77e-25	101
C103_contig_851_73	SARG|gi|446026113|ref|WP_000103968.1|	28.9	218	300	306	3.77e-25	101
C103_contig_851_73	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	26.5	302	300	306	3.77e-25	101
C103_contig_851_73	SARG|gi|510143239|gb|AGN36970.1|	26.5	302	300	313	4.23e-25	101
C103_contig_851_73	SARG|gi|542061059|gb|ERI11611.1|	25.7	303	300	316	6.14e-25	100
C103_contig_851_73	SARG|gi|447195835|ref|WP_001273091.1|	27.1	303	300	306	1.00e-24	100
C103_contig_851_73	SARG|gi|447195836|ref|WP_001273092.1|	27.1	303	300	306	1.00e-24	100
C103_contig_851_73	SARG|ABB80128	29.4	218	300	306	1.39e-24	99.8
C103_contig_851_73	SARG|gi|500194536|ref|WP_011867743.1|	31.6	215	300	306	1.39e-24	99.8
C103_contig_851_79	SARG|ZP_02848503	40.4	225	228	221	5.24e-58	182
C103_contig_851_79	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	41.5	224	228	220	3.29e-56	177
C103_contig_851_79	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	41.5	224	228	219	6.40e-56	176
C103_contig_851_79	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	41.5	224	228	220	6.60e-56	176
C103_contig_851_79	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	41.1	224	228	219	5.15e-55	174
C103_contig_851_79	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	41.1	224	228	220	3.01e-54	172
C103_contig_851_79	CARD|gb|ATC67679.1|ARO:3000838|arlR	39.2	227	228	219	1.07e-51	166
C103_contig_851_79	NCBI|WP_063856722.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	34.7	236	228	232	3.18e-42	142
C103_contig_851_79	NCBI|WP_063856727.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	34.9	235	228	232	4.48e-42	141
C103_contig_851_79	NCBI|WP_016295750.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	34.9	235	228	232	6.33e-42	141
C103_contig_851_80	megares|MEG_7501|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	28.8	257	520	354	1.03e-24	104
C103_contig_851_80	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	30.8	240	520	381	4.95e-24	102
C103_contig_851_80	megares|MEG_7504|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	30.8	240	520	381	4.95e-24	102
C103_contig_851_80	megares|MEG_7503|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	28.0	257	520	354	8.61e-24	101
C103_contig_851_80	megares|MEG_7497|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	28.0	257	520	376	1.15e-23	101
C103_contig_851_80	NCBI|WP_034869172.1|1|1|vanS-C|vanS-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-C|AMR|glycopeptide	28.0	257	520	376	1.15e-23	101
C103_contig_851_80	megares|MEG_7500|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	27.6	257	520	352	6.96e-23	99.0
C103_contig_851_80	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	25.4	334	520	364	2.20e-21	94.7
C103_contig_851_80	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	25.4	334	520	364	2.20e-21	94.7
C103_contig_851_80	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	28.3	219	520	359	2.80e-21	94.4
C103_contig_851_89	SARG|gi|917229923|ref|WP_051836635.1|	30.0	577	747	620	2.22e-64	224
C103_contig_851_89	SARG|gi|926351744|ref|WP_053683383.1|	30.0	577	747	648	9.80e-64	223
C103_contig_851_89	SARG|gi|919568551|ref|WP_052871170.1|	30.6	578	747	620	1.53e-63	222
C103_contig_851_89	SARG|gi|921231571|ref|WP_053176464.1|	30.6	578	747	620	4.01e-63	221
C103_contig_851_89	SARG|gi|917172177|ref|WP_051778889.1|	30.6	578	747	620	5.53e-63	221
C103_contig_851_89	SARG|gi|772774655|ref|WP_045322518.1|	30.0	587	747	620	7.62e-63	220
C103_contig_851_89	SARG|gi|496018010|ref|WP_008742581.1|	29.8	577	747	623	8.06e-63	220
C103_contig_851_89	SARG|gi|948137056|ref|WP_056795395.1|	28.9	608	747	602	1.03e-62	219
C103_contig_851_89	SARG|gi|799286378|ref|WP_045936958.1|	30.0	587	747	620	2.75e-62	219
C103_contig_851_89	SARG|gi|917127754|ref|WP_051734466.1|	30.0	587	747	620	2.75e-62	219
C103_contig_851_90	SARG|gi|930482089|ref|WP_054228897.1|	41.3	240	729	599	2.07e-46	173
C103_contig_851_90	SARG|gi|985844137|ref|WP_060895163.1|	41.3	240	729	599	2.07e-46	173
C103_contig_851_90	SARG|gi|943938624|ref|WP_055567802.1|	40.8	240	729	602	2.16e-46	173
C103_contig_851_90	SARG|gi|695865802|ref|WP_032778631.1|	28.7	561	729	605	3.06e-46	173
C103_contig_851_90	SARG|gi|917203192|ref|WP_051809904.1|	41.8	244	729	620	3.73e-46	173
C103_contig_851_90	SARG|gi|944470764|ref|WP_055701183.1|	41.7	240	729	601	3.94e-46	172
C103_contig_851_90	SARG|gi|1011969930|ref|WP_062776015.1|	40.8	240	729	601	3.94e-46	172
C103_contig_851_90	SARG|gi|764446018|ref|WP_044369325.1|	28.7	561	729	605	4.16e-46	172
C103_contig_851_90	SARG|gi|860594225|ref|WP_048475168.1|	42.5	240	729	620	5.06e-46	172
C103_contig_851_90	SARG|gi|926376632|ref|WP_053705806.1|	41.8	244	729	620	5.06e-46	172
C103_contig_851_102	SARG|gb|AAV85982.1|ARO:3000535|macB	37.8	315	1255	644	6.42e-51	190
C103_contig_851_102	SARG|gi|696420214|ref|WP_032990021.1|	36.1	313	1255	647	6.71e-51	190
C103_contig_851_102	SARG|gi|938460528|ref|WP_054624864.1|	36.1	313	1255	647	9.01e-51	190
C103_contig_851_102	SARG|gi|506220920|ref|WP_015740695.1|	36.4	313	1255	647	9.01e-51	190
C103_contig_851_102	SARG|gi|1020141879|ref|WP_063264839.1|	36.1	313	1255	647	9.01e-51	190
C103_contig_851_102	SARG|gi|490522515|ref|WP_004387938.1|	36.1	313	1255	647	9.01e-51	190
C103_contig_851_102	SARG|YP_001438541	36.1	313	1255	647	1.63e-50	189
C103_contig_851_102	SARG|gi|696411918|ref|WP_032982657.1|	36.1	313	1255	647	1.63e-50	189
C103_contig_851_102	SARG|gi|498115003|ref|WP_010429159.1|	37.2	298	1255	646	2.15e-50	189
C103_contig_851_102	SARG|gi|696402390|ref|WP_032974230.1|	36.1	313	1255	647	2.18e-50	189
C103_contig_851_125	SARG|gb|AAK76137.1|ARO:3000024|patA	28.7	216	247	564	2.85e-16	76.6
C103_contig_851_134	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	27.7	610	658	579	3.98e-67	229
C103_contig_851_134	SARG|gb|AAC74000.1|ARO:3003950|msbA	28.3	587	658	582	2.19e-66	227
C103_contig_851_134	SARG|gi|944152509|ref|WP_055644808.1|	28.7	596	658	616	8.36e-66	226
C103_contig_851_134	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	27.9	616	658	579	3.93e-65	224
C103_contig_851_134	SARG|gi|664180077|ref|WP_030714054.1|	27.5	590	658	605	1.27e-64	223
C103_contig_851_134	SARG|gb|WP_104671188.1|ARO:3003948|efrA	29.5	560	658	575	1.34e-64	222
C103_contig_851_134	SARG|gi|1045390184|ref|WP_065479071.1|	28.0	590	658	605	1.76e-64	223
C103_contig_851_134	SARG|gi|497748188|ref|WP_010062372.1|	27.5	590	658	605	4.69e-64	221
C103_contig_851_134	SARG|gi|764446018|ref|WP_044369325.1|	27.3	590	658	605	4.69e-64	221
C103_contig_851_134	SARG|gi|695842130|ref|WP_032755430.1|	28.1	594	658	603	6.25e-64	221
C103_contig_851_135	SARG|gi|948137056|ref|WP_056795395.1|	33.0	597	608	602	1.07e-82	270
C103_contig_851_135	SARG|gi|664458452|ref|WP_030980047.1|	33.2	591	608	601	4.18e-81	266
C103_contig_851_135	SARG|gi|953808775|ref|WP_058042812.1|	32.1	599	608	608	1.00e-79	262
C103_contig_851_135	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	33.3	559	608	579	1.39e-79	261
C103_contig_851_135	SARG|gi|817122037|ref|WP_046494699.1|	31.3	594	608	613	2.19e-79	261
C103_contig_851_135	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	31.8	595	608	579	7.44e-79	259
C103_contig_851_135	SARG|gb|AAK76136.1|ARO:3000025|patB	30.5	590	608	588	1.87e-77	256
C103_contig_851_135	SARG|gb|AYV52072.1|ARO:3002882|lmrD	33.1	544	608	664	7.18e-76	253
C103_contig_851_135	SARG|gb|CDO61516.1|ARO:3003949|efrB	39.3	346	608	362	1.73e-69	228
C103_contig_851_135	SARG|gb|AAK76137.1|ARO:3000024|patA	30.9	505	608	564	5.35e-67	227
C103_contig_851_158	SARG|gi|447195835|ref|WP_001273091.1|	28.2	220	509	306	2.05e-22	96.7
C103_contig_851_158	SARG|ZP_04081918	28.4	222	509	306	5.13e-22	95.5
C103_contig_851_158	SARG|gi|447195836|ref|WP_001273092.1|	27.7	220	509	306	5.13e-22	95.5
C103_contig_851_158	SARG|YP_002850060	30.0	227	509	648	7.02e-22	98.2
C103_contig_851_158	SARG|gi|500465078|gb|EOP76697.1|	26.8	220	509	306	9.42e-22	94.7
C103_contig_851_158	SARG|gi|500448961|gb|EOP61695.1|	26.8	220	509	306	1.28e-21	94.4
C103_contig_851_158	SARG|gi|495067432|ref|WP_007792257.1|	28.6	227	509	647	1.65e-21	97.1
C103_contig_851_158	SARG|gi|696368937|ref|WP_032943949.1|	30.0	227	509	648	1.66e-21	97.1
C103_contig_851_158	SARG|gi|851913025|ref|WP_048215946.1|	30.0	227	509	648	1.66e-21	97.1
C103_contig_851_158	SARG|gi|489930965|ref|WP_003834285.1|	30.0	227	509	648	1.66e-21	97.1
C103_contig_851_167	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	40.8	228	226	232	7.77e-57	179
C103_contig_851_167	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	40.8	228	226	232	7.77e-57	179
C103_contig_851_167	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	40.8	228	226	231	1.77e-52	168
C103_contig_851_167	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	40.8	228	226	231	1.77e-52	168
C103_contig_851_167	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	37.1	232	226	230	3.45e-52	167
C103_contig_851_167	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	38.5	221	226	220	7.27e-52	166
C103_contig_851_167	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	38.5	221	226	219	9.98e-52	166
C103_contig_851_167	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	38.5	221	226	220	1.03e-51	166
C103_contig_851_167	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	38.7	230	226	231	2.84e-51	165
C103_contig_851_167	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	38.0	221	226	219	8.00e-51	163
C103_contig_851_168	NCBI|WP_002382867.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	27.3	311	506	447	9.44e-31	123
C103_contig_851_168	NCBI|WP_012579101.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	27.3	311	506	447	9.44e-31	123
C103_contig_851_168	NCBI|WP_063856739.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	27.3	311	506	447	9.44e-31	123
C103_contig_851_168	NCBI|WP_002368696.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	27.1	310	506	447	4.41e-30	121
C103_contig_851_168	NCBI|WP_063856751.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	26.7	311	506	454	4.09e-29	118
C103_contig_851_168	CARD|gb|ABD30512.1|ARO:3000839|arlS	21.9	342	506	451	5.99e-21	94.4
C103_contig_851_168	NCBI|WP_063856742.1|1|1|vanS-Pt|vanS-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt|AMR|glycopeptide	24.7	275	506	388	1.31e-18	86.7
C103_contig_851_168	megares|MEG_7489|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	24.7	275	506	388	1.31e-18	86.7
C103_contig_851_168	NCBI|WP_063856741.1|1|1|vanS-Pt|vanS-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt|AMR|glycopeptide	24.7	275	506	386	3.11e-18	85.5
C103_contig_851_168	megares|MEG_7488|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	24.7	275	506	386	3.11e-18	85.5
C103_contig_851_180	NCBI|WP_063856700.1|1|1|vanH-Ao2|vanH-Ao2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ao2|AMR|glycopeptide	28.7	216	388	343	7.93e-18	82.8
C103_contig_851_180	NCBI|WP_063856699.1|1|1|vanH-Ao1|vanH-Ao1|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ao1|AMR|glycopeptide	28.7	216	388	348	8.31e-18	82.8
C103_contig_851_180	NCBI|WP_011029109.1|1|1|vanH-Sc|vanH-Sc|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Sc|AMR|glycopeptide	29.4	218	388	337	1.53e-16	79.0
C103_contig_851_180	SARG|gi|749574782|ref|WP_040203616.1|	28.5	221	388	323	6.60e-15	73.9
C103_contig_851_180	SARG|gi|740152780|ref|WP_037997109.1|	28.1	221	388	322	8.82e-15	73.6
C103_contig_851_180	SARG|KF478993.1.gene2.p01	28.9	218	388	350	2.66e-14	72.4
C103_contig_851_180	SARG|AAY52004	23.9	264	388	322	5.25e-14	71.2
C103_contig_851_180	SARG|gb|MBY8651254.1|ARO:3007188|vanH_in_vanP_cl	24.7	263	388	314	3.09e-12	65.9
C103_contig_851_187	SARG|gi|1035670474|ref|WP_064517458.1|	33.9	245	383	648	1.62e-30	122
C103_contig_851_187	SARG|gi|1035717981|ref|WP_064557480.1|	33.9	245	383	648	1.62e-30	122
C103_contig_851_187	SARG|gi|502669352|ref|WP_012905216.1|	35.5	220	383	648	2.97e-30	121
C103_contig_851_187	SARG|gi|1035706844|ref|WP_064548272.1|	34.2	234	383	648	7.36e-30	120
C103_contig_851_187	SARG|gi|803568669|ref|WP_046077412.1|	35.8	218	383	648	1.82e-29	119
C103_contig_851_187	SARG|gi|446110352|ref|WP_000188207.1|	35.8	218	383	648	1.82e-29	119
C103_contig_851_187	SARG|YP_002382193	35.8	218	383	648	1.82e-29	119
C103_contig_851_187	SARG|gi|803575554|ref|WP_046081557.1|	35.8	218	383	648	1.82e-29	119
C103_contig_851_187	SARG|gi|446110351|ref|WP_000188206.1|	35.8	218	383	648	1.82e-29	119
C103_contig_851_187	SARG|gi|736472622|ref|WP_034494292.1|	35.0	220	383	648	6.10e-29	117
C103_contig_851_190	SARG|gb|ADZ12699.1|ARO:3005091|RanA	33.2	250	348	258	8.67e-36	129
C103_contig_851_190	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	32.3	223	348	255	1.30e-31	118
C103_contig_851_190	SARG|gi|895865878|ref|WP_048974758.1|	32.7	223	348	646	2.90e-27	111
C103_contig_851_273	SARG|Q47748	36.1	313	330	323	3.50e-59	192
C103_contig_851_273	SARG|gb|AAB05626.1|ARO:3002943|vanHB	36.1	313	330	323	6.95e-59	191
C103_contig_851_273	SARG|YP_002333394	35.0	311	330	323	6.00e-57	186
C103_contig_851_273	NCBI|WP_063856701.1|1|1|vanH-B|vanH-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-B|AMR|glycopeptide	35.0	311	330	323	6.00e-57	186
C103_contig_851_273	SARG|AF310956.2.gene5.p01	35.0	311	330	323	8.45e-57	186
C103_contig_851_273	SARG|FJ349556.1.gene5.p01	34.1	311	330	326	2.56e-56	184
C103_contig_851_273	SARG|AAF72362	34.5	313	330	323	7.24e-55	181
C103_contig_851_273	NCBI|WP_011029109.1|1|1|vanH-Sc|vanH-Sc|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Sc|AMR|glycopeptide	34.0	312	330	337	1.48e-54	180
C103_contig_851_273	NCBI|WP_063856710.1|1|1|vanH-Pt2|vanH-Pt2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Pt2|AMR|glycopeptide	33.1	320	330	322	1.09e-53	177
C103_contig_851_273	SARG|NP_878015	33.1	311	330	322	1.53e-53	177
C103_contig_851_276	SARG|ABF69686	23.0	701	697	639	8.52e-46	172
C103_contig_851_276	SARG|Q08425	23.3	674	697	641	1.18e-45	171
C103_contig_851_276	megares|MEG_7181|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETQ_1	23.3	674	697	657	1.42e-45	171
C103_contig_851_276	SARG|Z21523.gene.p01	23.3	674	697	657	1.42e-45	171
C103_contig_851_276	NCBI|WP_013646121.1|1|1|tet(O/W/32/O)|tet(O/W/32/O)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_mosaic_protein_Tet(O/W/32/O)|AMR|tetracycline	23.0	691	697	639	2.90e-45	170
C103_contig_851_276	SARG|ABG81258	23.0	701	697	639	3.94e-45	170
C103_contig_851_276	NCBI|WP_063856408.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	23.1	674	697	654	6.32e-45	169
C103_contig_851_276	megares|MEG_7182|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETQ_1	23.1	674	697	670	7.47e-45	169
C103_contig_851_276	SARG|AAB51122	23.1	674	697	670	7.47e-45	169
C103_contig_851_276	megares|MEG_7167|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	23.0	691	697	639	9.84e-45	169
C103_contig_851_278	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.5	501	519	655	3.18e-84	273
C103_contig_851_278	SARG|gb|AKA86814|ARO:3003746|optrA	31.5	501	519	655	3.18e-84	273
C103_contig_851_278	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.5	501	519	655	8.73e-84	271
C103_contig_851_278	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.5	501	519	655	8.73e-84	271
C103_contig_851_278	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.5	501	519	655	8.73e-84	271
C103_contig_851_278	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.5	501	519	655	1.22e-83	271
C103_contig_851_278	megares|MEG_4323|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.5	501	519	655	1.71e-83	271
C103_contig_851_278	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.3	501	519	655	3.36e-83	270
C103_contig_851_278	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.3	501	519	655	6.58e-83	269
C103_contig_851_278	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.3	501	519	655	6.58e-83	269
C103_contig_851_303	SARG|gi|921231571|ref|WP_053176464.1|	31.7	584	583	620	1.82e-97	308
C103_contig_851_303	SARG|gi|917172177|ref|WP_051778889.1|	31.7	584	583	620	2.55e-97	308
C103_contig_851_303	SARG|gi|919568551|ref|WP_052871170.1|	31.5	584	583	620	5.03e-97	307
C103_contig_851_303	SARG|gi|496018010|ref|WP_008742581.1|	31.1	586	583	623	1.07e-96	306
C103_contig_851_303	SARG|gi|926351744|ref|WP_053683383.1|	31.2	586	583	648	3.95e-96	306
C103_contig_851_303	SARG|gi|1045390184|ref|WP_065479071.1|	29.7	582	583	605	7.28e-96	304
C103_contig_851_303	SARG|gi|663350985|ref|WP_030349761.1|	31.2	583	583	613	1.25e-95	303
C103_contig_851_303	SARG|gi|926400371|ref|WP_053728483.1|	30.6	588	583	603	1.92e-95	303
C103_contig_851_303	SARG|gi|497748188|ref|WP_010062372.1|	29.6	584	583	605	2.02e-95	303
C103_contig_851_303	SARG|gi|917166849|ref|WP_051773561.1|	31.2	584	583	620	2.10e-95	303
C103_contig_851_335	megares|MEG_5400|Drugs|beta-lactam|Penicillin_binding_protein|PBP2_1	24.2	459	478	633	2.04e-16	80.9
C103_contig_851_367	SARG|gb|AAG05187.1|ARO:3005067|ParS	26.0	219	1205	428	4.94e-13	71.6
C103_contig_851_385	CARD|gb|AAC75429.1|ARO:3000833|evgS	29.7	397	702	1197	5.05e-39	154
C103_contig_851_385	CARD|gb|AEX49906.1|ARO:3003583|basS	26.3	228	702	477	1.68e-14	75.5
C103_contig_851_385	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	30.3	119	702	231	3.41e-11	62.8
C103_contig_851_385	CARD|gb|AAG06465.1|ARO:3005063|cprR	31.5	127	702	223	2.70e-09	57.0
C103_contig_851_385	CARD|gb|ATC67679.1|ARO:3000838|arlR	25.4	126	702	219	3.45e-09	56.6
C103_contig_851_385	CARD|gb|ADM92605.1|ARO:3000553|adeR	32.7	113	702	247	1.24e-07	52.4
C103_contig_851_389	SARG|gb|CAE00499.1|ARO:3003835|cdeA	27.8	417	454	441	1.23e-40	149
C103_contig_851_389	SARG|gi|488374619|ref|WP_002444004.1|	25.0	432	454	452	1.82e-33	130
C103_contig_851_389	SARG|HE999704.1.gene3064.p01	34.0	206	454	241	5.56e-33	124
C103_contig_851_389	SARG|YP_302230	25.7	421	454	451	2.75e-31	124
C103_contig_851_389	SARG|gi|505177635|ref|WP_015364737.1|	24.7	433	454	451	5.15e-31	123
C103_contig_851_389	SARG|ZP_04679156	24.9	434	454	451	1.79e-30	121
C103_contig_851_389	SARG|gi|537465183|ref|WP_020976941.1|	24.5	432	454	451	1.16e-29	119
C103_contig_851_389	SARG|gi|565830932|ref|WP_023914633.1|	24.5	432	454	451	2.15e-29	118
C103_contig_851_389	SARG|gi|446573700|ref|WP_000651046.1|	24.5	432	454	451	2.94e-29	118
C103_contig_851_389	SARG|gi|446573707|ref|WP_000651053.1|	24.5	432	454	451	4.00e-29	117
C103_contig_851_393	CARD|gb|CYF42523.1|ARO:3004047|kdpD	29.3	502	571	885	3.13e-63	222
C103_contig_851_393	CARD|gb|ADM92606.1|ARO:3000549|adeS	28.1	235	571	361	2.47e-17	82.8
C103_contig_851_394	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	44.1	227	240	225	3.75e-62	193
C103_contig_851_394	CARD|gb|AAC73788.1|ARO:3003841|kdpE	44.1	227	240	225	3.75e-62	193
C103_contig_851_394	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	36.7	229	240	231	5.12e-44	147
C103_contig_851_394	CARD|gb|ATC67679.1|ARO:3000838|arlR	39.3	224	240	219	5.16e-44	146
C103_contig_851_394	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	35.1	228	240	232	2.95e-43	145
C103_contig_851_394	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	32.7	223	240	228	1.64e-41	140
C103_contig_851_394	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	33.6	226	240	232	8.04e-40	136
C103_contig_851_394	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	33.6	226	240	232	8.04e-40	136
C103_contig_851_394	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	31.5	222	240	229	2.93e-39	134
C103_contig_851_394	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	34.8	230	240	239	3.82e-39	134
C103_contig_851_405	SARG|M58472.1.gene1.p01	38.5	52	195	209	1.55e-06	45.8
C103_contig_851_405	NCBI|WP_031281281.1|1|1|catB|catB|acetyltransferase|2|CHLORAMPHENICOL|PHENICOL|type_B_phenicol_O-acetyltransferase|AMR|phenicol	40.4	52	195	210	3.93e-06	44.7
C103_contig_851_409	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	36.2	116	393	231	1.10e-11	63.2
C103_contig_851_409	CARD|gb|ATC67679.1|ARO:3000838|arlR	31.4	105	393	219	4.22e-08	52.4
C103_contig_851_409	CARD|gb|BAB36671.1|ARO:3000832|evgA	27.7	83	393	204	8.70e-08	51.2
C103_contig_851_409	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	31.0	113	393	228	1.52e-07	50.8
C103_contig_851_409	CARD|gb|ADM92605.1|ARO:3000553|adeR	30.4	102	393	247	7.80e-07	48.9
C103_contig_851_409	CARD|gb|AAG06465.1|ARO:3005063|cprR	27.1	96	393	223	1.15e-06	48.1
C103_contig_851_418	CARD|gb|AAC75429.1|ARO:3000833|evgS	29.6	375	733	1197	8.86e-39	154
C103_contig_851_418	megares|MEG_7500|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	26.6	263	733	352	8.42e-16	78.6
C103_contig_851_418	megares|MEG_7497|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	26.6	263	733	376	1.04e-15	78.6
C103_contig_851_418	NCBI|WP_034869172.1|1|1|vanS-C|vanS-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-C|AMR|glycopeptide	26.6	263	733	376	1.04e-15	78.6
C103_contig_851_418	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	25.3	241	733	364	2.25e-15	77.4
C103_contig_851_418	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	25.3	241	733	364	2.25e-15	77.4
C103_contig_851_418	megares|MEG_7501|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	25.6	281	733	354	2.75e-15	77.0
C103_contig_851_418	megares|MEG_7503|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	26.4	265	733	354	8.80e-15	75.5
C103_contig_851_418	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	29.7	138	733	232	2.21e-13	69.3
C103_contig_851_418	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	26.1	238	733	381	2.57e-13	71.2
C103_contig_851_420	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	26.5	226	984	359	1.17e-19	90.9
C103_contig_851_420	CARD|gb|ADM92606.1|ARO:3000549|adeS	25.7	245	984	361	7.54e-17	82.4
C103_contig_851_420	CARD|gb|AAC75429.1|ARO:3000833|evgS	35.8	134	984	1197	4.55e-14	75.9
C103_contig_851_420	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	32.2	118	984	219	5.76e-11	62.4
C103_contig_851_420	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	32.2	118	984	219	5.76e-11	62.4
C103_contig_851_420	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	32.2	118	984	220	5.85e-11	62.4
C103_contig_851_420	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	32.2	118	984	220	7.90e-11	62.0
C103_contig_851_420	CARD|gb|ADM92605.1|ARO:3000553|adeR	32.3	124	984	247	5.15e-10	60.1
C103_contig_851_420	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	28.9	121	984	232	5.69e-10	59.7
C103_contig_851_420	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	31.4	118	984	220	2.88e-09	57.4
C103_contig_851_421	CARD|gb|AAC75429.1|ARO:3000833|evgS	29.2	401	956	1197	8.33e-48	184
C103_contig_851_421	CARD|gb|AEX49906.1|ARO:3003583|basS	25.9	247	956	477	2.03e-14	75.9
C103_contig_851_421	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	30.1	123	956	231	1.83e-12	67.0
C103_contig_851_421	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	30.7	127	956	232	4.58e-12	65.9
C103_contig_851_424	SARG|M58472.1.gene1.p01	40.4	52	128	209	1.65e-07	47.0
C103_contig_851_424	NCBI|WP_031281281.1|1|1|catB|catB|acetyltransferase|2|CHLORAMPHENICOL|PHENICOL|type_B_phenicol_O-acetyltransferase|AMR|phenicol	40.4	52	128	210	4.33e-07	45.8
C103_contig_851_424	SARG|CAP74085	31.0	71	128	210	8.18e-07	45.1
C103_contig_851_424	SARG|gi|499386493|ref|WP_011073960.1|	37.5	56	128	210	1.54e-06	44.3
C103_contig_851_424	SARG|ABF20240	31.0	71	128	210	7.51e-06	42.4
C103_contig_851_424	NCBI|WP_071846375.1|1|1|catB3|catB3|acetyltransferase|2|CHLORAMPHENICOL|PHENICOL|type_B-3_phenicol_O-acetyltransferase_CatB3|AMR|phenicol	29.6	71	128	210	7.51e-06	42.4
C103_contig_851_424	NCBI|WP_071766400.1|1|1|catB8|catB8|acetyltransferase|2|CHLORAMPHENICOL|PHENICOL|type_B-3_phenicol_O-acetyltransferase_CatB8|AMR|phenicol	31.0	71	128	210	7.51e-06	42.4
C103_contig_851_439	NCBI|WP_005812825.1|1|1|nimJ|nimJ|nitroimidazole_reductase|2|NITROIMIDAZOLE|NITROIMIDAZOLE|5-nitroimidazole_reductase_NimJ|AMR|nitroimidazole	38.5	156	160	165	5.64e-26	95.9
C103_contig_851_439	NCBI|WP_087312253.1|1|1|nimG|nimG||2|NITROIMIDAZOLE|NITROIMIDAZOLE|5-nitroimidazole_reductase_NimG|AMR|nitroimidazole	38.3	154	160	164	8.66e-25	92.8
C103_contig_851_439	NCBI|WP_005812773.1|1|1|nimE|nimE|nitroimidazole_reductase|2|NITROIMIDAZOLE|NITROIMIDAZOLE|5-nitroimidazole_reductase_NimE|AMR|nitroimidazole	39.5	167	160	170	1.42e-24	92.4
C103_contig_851_439	NCBI|WP_032488596.1|1|1|nimA|nimA|nitroimidazole_reductase|2|NITROIMIDAZOLE|NITROIMIDAZOLE|5-nitroimidazole_reductase_NimA|AMR|nitroimidazole	38.3	154	160	176	3.26e-24	91.7
C103_contig_851_439	ResF|nimE_1_AJ244018_1	40.1	167	160	170	5.61e-24	90.9
C103_contig_851_439	megares|MEG_4185|Drugs|Metronidazole|nim_nitroimidazole_reductase|NIME_1	39.9	158	160	152	1.01e-23	89.7
C103_contig_851_439	NCBI|WP_063854490.1|1|1|nimB|nimB|nitroimidazole_reductase|2|NITROIMIDAZOLE|NITROIMIDAZOLE|5-nitroimidazole_reductase_NimB|AMR|nitroimidazole	38.3	154	160	164	2.70e-23	89.0
C103_contig_851_439	NCBI|WP_063854492.1|1|1|nimD|nimD|nitroimidazole_reductase|2|NITROIMIDAZOLE|NITROIMIDAZOLE|5-nitroimidazole_reductase_NimD|AMR|nitroimidazole	37.0	154	160	164	7.56e-23	87.8
C103_contig_851_439	megares|MEG_4184|Drugs|Metronidazole|nim_nitroimidazole_reductase|NIME_1	43.9	107	160	145	1.04e-21	84.3
C103_contig_851_439	NCBI|CBE03766.1|1|1|nimB-Cd|nimB-Cd||1|NITROIMIDAZOLE|NITROIMIDAZOLE|putative_5-nitroimidazole_reductase_NimB-Cd|AMR|nitroimidazole	30.4	158	160	155	1.92e-17	73.6
C103_contig_851_451	SARG|gb|WP_104671188.1|ARO:3003948|efrA	40.8	573	581	575	3.17e-140	417
C103_contig_851_451	SARG|gb|AAK76137.1|ARO:3000024|patA	35.4	517	581	564	1.09e-101	318
C103_contig_851_451	SARG|gi|860594225|ref|WP_048475168.1|	28.8	572	581	620	1.29e-64	221
C103_contig_851_451	SARG|gi|664170108|ref|WP_030704355.1|	29.4	571	581	603	4.82e-64	219
C103_contig_851_451	SARG|gi|928900436|ref|WP_053931243.1|	28.4	567	581	600	8.79e-64	219
C103_contig_851_451	SARG|gi|664579989|ref|WP_031094015.1|	28.4	567	581	601	8.96e-64	219
C103_contig_851_451	SARG|gi|951183771|ref|WP_057661487.1|	29.4	571	581	603	9.31e-64	219
C103_contig_851_451	SARG|gi|1045390184|ref|WP_065479071.1|	28.4	567	581	605	9.67e-64	219
C103_contig_851_451	SARG|gi|490068471|ref|WP_003970646.1|	29.4	571	581	603	1.29e-63	218
C103_contig_851_451	SARG|gi|664042835|ref|WP_030582300.1|	29.4	571	581	604	1.32e-63	218
C103_contig_851_452	SARG|gb|AAK76136.1|ARO:3000025|patB	33.7	569	595	588	4.42e-105	328
C103_contig_851_452	SARG|gb|AYV52072.1|ARO:3002882|lmrD	35.6	520	595	664	3.64e-98	312
C103_contig_851_452	SARG|gb|CDO61516.1|ARO:3003949|efrB	45.5	332	595	362	1.69e-88	277
C103_contig_851_452	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	32.4	568	595	579	2.26e-83	271
C103_contig_851_452	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	32.7	565	595	579	4.42e-83	270
C103_contig_851_452	SARG|gb|AAC74000.1|ARO:3003950|msbA	30.3	509	595	582	9.33e-83	269
C103_contig_851_452	SARG|gi|948137056|ref|WP_056795395.1|	33.3	501	595	602	2.52e-78	258
C103_contig_851_452	SARG|gi|928900436|ref|WP_053931243.1|	32.9	499	595	600	2.50e-77	255
C103_contig_851_452	SARG|gi|664579989|ref|WP_031094015.1|	32.9	499	595	601	2.56e-77	255
C103_contig_851_452	SARG|gi|944152509|ref|WP_055644808.1|	33.3	502	595	616	1.90e-76	253
C103_contig_851_494	SARG|ZP_04081918	22.8	228	367	306	1.19e-14	72.8
C103_contig_851_494	SARG|gb|AHB37625.1|ARO:3004715|vga(E)	23.6	225	367	524	1.69e-11	64.3
C103_contig_851_494	SARG|FR772051.1.gene9.p01	22.2	225	367	524	5.32e-11	62.8
C103_contig_851_494	CARD|gb|BAB80490.1|ARO:3007644|Cper_cplR	26.1	211	367	568	3.10e-10	60.5
C103_contig_851_494	SARG|gi|686436876|ref|WP_031922735.1|	26.8	213	367	491	2.02e-08	54.7
C103_contig_851_494	SARG|ABA02367	25.7	222	367	488	6.26e-08	53.1
C103_contig_851_494	SARG|gi|127359|sp|P23212.1|MSRA_STAEP	25.7	222	367	488	6.26e-08	53.1
C103_contig_851_494	SARG|gb|CAA36304.1|ARO:3000251|msrA	25.7	222	367	488	6.26e-08	53.1
C103_contig_851_494	SARG|BAD86537	25.7	222	367	488	6.26e-08	53.1
C103_contig_851_494	SARG|YP_254220	26.1	222	367	488	8.31e-08	52.8
C103_contig_851_496	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	24.6	114	251	228	3.26e-06	45.8
C103_contig_851_502	SARG|gb|BAD89844.2|ARO:3000753|abeM	21.7	405	458	448	3.34e-11	63.9
C103_contig_851_502	NCBI|EFF39147.1|1|1|norM-NG|norM-NG|efflux|1|EFFLUX|EFFLUX|sodium-coupled_multidrug_efflux_MATE_transporter_NorM|AMR|efflux	20.0	434	458	459	1.02e-09	59.3
C103_contig_851_502	SARG|NC_011035.1.6448920.p01	20.0	434	458	459	1.02e-09	59.3
C103_contig_851_502	SARG|gi|488158065|ref|WP_002229273.1|	19.9	376	458	459	7.32e-09	56.6
C103_contig_851_502	SARG|gi|488156254|ref|WP_002227462.1|	19.9	376	458	459	7.32e-09	56.6
C103_contig_851_502	SARG|gi|489863287|ref|WP_003766901.1|	19.9	432	458	459	3.96e-08	54.3
C103_contig_851_522	NCBI|WP_000369216.1|1|1|mecI_of_mecA|mecI_of_mecA||2|METHICILLIN|beta-lactam|mecA-type_methicillin_resistance_repressor_MecI|AMR|beta-lactam	27.4	117	123	123	3.23e-14	63.2
C103_contig_851_568	SARG|gb|AQX82857.1|ARO:3004185|mecD	26.5	355	966	678	4.79e-18	88.2
C103_contig_851_568	NCBI|WP_063852710.1|1|1|mecB|mecB|insensitivity|2|METHICILLIN|beta-lactam|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecB|AMR|beta-lactam	27.0	337	966	674	5.17e-16	81.6
C103_contig_851_568	SARG|gb|BAI83385.1|ARO:3003440|mecB	27.0	337	966	674	6.80e-16	81.3
C103_contig_851_568	ResF|penA_1_AF515059_1	23.1	389	966	581	4.76e-11	65.5
C103_contig_851_576	NCBI|AKA30736.1|1|1|cxpE|cxpE||1|CHLORAMPHENICOL|PHENICOL|phenicol_efflux_transporter_CxpE|AMR|phenicol	24.1	257	480	397	5.66e-12	66.2
C103_contig_258_19	megares|MEG_5148|Drugs|beta-lactam|Class_D_betalactamases|OXA_1	25.7	311	294	346	6.49e-21	90.1
C103_contig_258_27	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	29.9	144	269	231	5.19e-11	60.1
C103_contig_258_27	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	27.2	151	269	232	8.35e-10	56.6
C103_contig_258_27	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	27.6	116	269	229	2.31e-08	52.4
C103_contig_258_27	CARD|gb|AAG06465.1|ARO:3005063|cprR	28.1	128	269	223	7.34e-08	50.8
C103_contig_258_39	SARG|Q08425	26.0	453	530	641	9.08e-35	137
C103_contig_258_39	megares|MEG_7181|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETQ_1	26.0	453	530	657	9.94e-35	137
C103_contig_258_39	SARG|Z21523.gene.p01	26.0	453	530	657	9.94e-35	137
C103_contig_258_39	NCBI|WP_063856408.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	26.0	453	530	654	1.32e-34	137
C103_contig_258_39	megares|MEG_7182|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETQ_1	26.0	453	530	670	1.43e-34	137
C103_contig_258_39	SARG|AAB51122	26.0	453	530	670	1.43e-34	137
C103_contig_258_39	SARG|Q52360	26.0	453	530	641	3.32e-33	132
C103_contig_258_39	SARG|P70882	25.6	453	530	641	3.32e-33	132
C103_contig_258_39	SARG|BAD46890	25.6	453	530	657	3.59e-33	132
C103_contig_258_39	NCBI|WP_063856409.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	25.8	453	530	641	1.09e-32	131
C103_contig_258_55	NCBI|ACF30254.1|1|1|mtrR|mtrR|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_system_transcriptional_repressor_MtrR|AMR|efflux	31.0	84	207	210	8.43e-06	43.9
C103_contig_258_55	NCBI|CAA81047.1|1|1|mtrR|mtrR|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_system_transcriptional_repressor_MtrR|AMR|efflux	31.0	84	207	210	8.43e-06	43.9
C103_contig_258_169	SARG|gb|AAC75089.1|ARO:3003577|ugd	49.4	83	98	388	5.54e-23	89.7
C103_contig_258_179	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	23.9	698	801	1033	3.47e-32	133
C103_contig_258_179	SARG|gb|AEY83581|ARO:3000510|mupB	23.9	698	801	1033	3.47e-32	133
C103_contig_258_179	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	22.8	710	801	1024	1.18e-29	125
C103_contig_258_179	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	22.8	710	801	1024	1.18e-29	125
C103_contig_258_179	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	22.8	710	801	1024	1.18e-29	125
C103_contig_258_179	SARG|gb|CAA53189|ARO:3000521|mupA	22.8	710	801	1024	1.18e-29	125
C103_contig_258_179	megares|MEG_3295|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|ILES_1	20.8	838	801	1107	2.74e-15	79.3
C103_contig_258_179	SARG|gb|ADP36409.1|ARO:3003730|Bifidobacteria	20.8	838	801	1107	2.74e-15	79.3
C103_contig_258_182	SARG|gb|ABX00624.1|ARO:3002881|lmrC	30.2	179	228	550	3.26e-11	61.2
C103_contig_258_182	NCBI|WP_171943877.1|1|1|vga(F)|vga(F)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(F)|AMR|lincosamide	35.9	78	228	461	1.48e-09	56.2
C103_contig_258_182	NCBI|WP_172065992.1|1|1|vga(F)|vga(F)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(F)|AMR|lincosamide	35.9	78	228	461	2.69e-09	55.5
C103_contig_258_182	NCBI|AJP12342.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	29.3	92	228	550	3.09e-08	52.4
C103_contig_258_182	CARD|gb|BAB80490.1|ARO:3007644|Cper_cplR	30.5	82	228	568	3.12e-08	52.4
C103_contig_258_182	SARG|KC539823.1.gene1.p01	31.4	86	228	522	3.41e-06	46.2
C103_contig_258_182	NCBI|WP_063856937.1|1|1|vga(A)|vga(A)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(A)|AMR|lincosamide	31.4	86	228	522	6.13e-06	45.4
C103_contig_258_182	NCBI|WP_032492560.1|1|1|vga(A)|vga(A)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(A)|AMR|lincosamide	31.4	86	228	522	8.21e-06	45.1
C103_contig_258_182	SARG|DQ823382.1.gene1.p01	31.4	86	228	522	8.21e-06	45.1
C103_contig_258_182	megares|MEG_7687|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|VGA_1	31.4	86	228	522	8.21e-06	45.1
C103_contig_258_202	CARD|gb|ALH22601.1|ARO:3000620|adeL	28.4	299	304	337	7.84e-19	84.3
C103_contig_258_256	SARG|gb|AAV85982.1|ARO:3000535|macB	32.1	234	260	644	1.32e-27	110
C103_contig_258_256	SARG|gi|664458452|ref|WP_030980047.1|	27.2	232	260	601	3.99e-12	64.7
C103_contig_258_256	SARG|gb|CDO61516.1|ARO:3003949|efrB	25.4	177	260	362	3.15e-11	61.6
C103_contig_258_256	SARG|gb|AVI44920.1|ARO:3004470|poxtA	22.8	224	260	542	6.13e-09	55.1
C103_contig_258_256	NCBI|WP_209691075.1|1|1|poxtA2|poxtA|target_protection|2|CHLORAMPHENICOL/FLORFENICOL/LINEZOLID|OXAZOLIDINONE/PHENICOL|ABC-F_type_ribosomal_protection_protein_PoxtA2|AMR|multidrug	22.8	224	260	544	6.14e-09	55.1
C103_contig_258_256	NCBI|WP_014936356.1|1|1|tva(B)|tva(B)|target_protection|2|TIAMULIN|PLEUROMUTILIN|ABC-F_type_ribosomal_protection_protein_Tva(B)|AMR|pleuromutilin	20.8	226	260	504	8.51e-07	48.5
C103_contig_258_275	SARG|gi|657888313|ref|WP_029592374.1|	46.4	224	225	648	2.47e-60	199
C103_contig_258_275	SARG|gi|851928815|ref|WP_048221086.1|	44.8	223	225	648	6.70e-60	197
C103_contig_258_275	SARG|gi|780033092|ref|WP_045444768.1|	44.8	223	225	648	6.70e-60	197
C103_contig_258_275	SARG|gi|742378414|ref|WP_038857601.1|	45.7	223	225	647	9.21e-60	197
C103_contig_258_275	SARG|gi|639225329|ref|WP_024561799.1|	46.0	224	225	648	9.35e-60	197
C103_contig_258_275	SARG|gi|639218559|ref|WP_024556062.1|	46.0	224	225	648	9.35e-60	197
C103_contig_258_275	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	42.3	222	225	255	1.43e-59	187
C103_contig_258_275	SARG|gi|1020141879|ref|WP_063264839.1|	45.7	223	225	647	1.79e-59	196
C103_contig_258_275	SARG|gi|1035670474|ref|WP_064517458.1|	45.3	223	225	648	1.82e-59	196
C103_contig_258_275	SARG|gi|1035717981|ref|WP_064557480.1|	45.3	223	225	648	1.82e-59	196
C103_contig_258_276	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	26.1	226	422	370	6.03e-20	89.7
C103_contig_258_276	CARD|gb|AEX49906.1|ARO:3003583|basS	26.5	238	422	477	5.31e-19	87.8
C103_contig_258_277	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	33.2	220	230	219	1.18e-32	117
C103_contig_258_277	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	33.2	220	230	220	1.21e-32	117
C103_contig_258_277	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	33.2	220	230	220	1.70e-32	116
C103_contig_258_277	CARD|gb|AAC73788.1|ARO:3003841|kdpE	29.7	222	230	225	1.92e-32	116
C103_contig_258_277	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	32.3	220	230	220	6.65e-32	115
C103_contig_258_277	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	29.7	219	230	225	7.53e-32	115
C103_contig_258_277	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	32.7	220	230	219	9.13e-32	114
C103_contig_258_277	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	30.2	225	230	231	4.78e-31	113
C103_contig_258_277	NCBI|XSG12259.1|1|1|drcR|drcR||1|||daptomycin_efflux_response_regulator_transcription_factor_DrcR|AMR|peptide	33.5	221	230	223	1.28e-28	106
C103_contig_258_277	SARG|ZP_02848503	31.8	220	230	221	1.31e-27	103
C103_contig_258_300	SARG|DQ212986.1.gene3.p01	37.3	75	76	75	4.97e-16	64.7
C103_contig_258_304	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	48.7	226	234	228	3.21e-70	213
C103_contig_258_304	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	43.3	224	234	231	4.76e-60	187
C103_contig_258_304	CARD|gb|ATC67679.1|ARO:3000838|arlR	42.3	222	234	219	3.03e-58	182
C103_contig_258_304	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	41.8	225	234	232	1.02e-56	179
C103_contig_258_304	CARD|gb|AAG05188.1|ARO:3005068|ParR	41.3	225	234	235	1.12e-56	179
C103_contig_258_304	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	41.7	228	234	232	1.45e-56	179
C103_contig_258_304	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	41.7	228	234	232	1.45e-56	179
C103_contig_258_304	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	40.3	233	234	235	3.60e-55	175
C103_contig_258_304	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	39.9	228	234	231	2.56e-54	173
C103_contig_258_304	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	39.9	228	234	231	3.62e-54	172
C103_contig_258_305	CARD|gb|AAD51347.1|ARO:3003067|smeS	30.7	257	502	467	2.80e-28	116
C103_contig_258_305	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	26.7	240	502	367	6.93e-26	107
C103_contig_258_305	NCBI|WP_021418927.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	26.7	240	502	368	7.03e-26	107
C103_contig_258_305	NCBI|AXB64455.1|1|1|vanS-Cd|vanS-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|VanG-Cd-type_glycopeptide_resistance_histidine_kinase_VanS|AMR|glycopeptide	28.9	211	502	380	1.74e-24	103
C103_contig_258_305	megares|MEG_7498|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	28.9	211	502	380	1.74e-24	103
C103_contig_258_305	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	28.4	243	502	364	1.61e-23	100
C103_contig_258_305	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	28.4	243	502	364	1.61e-23	100
C103_contig_258_305	megares|MEG_7502|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	28.1	221	502	361	2.60e-21	94.4
C103_contig_258_305	NCBI|WP_063856733.1|1|1|vanS-C|vanS-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-C|AMR|glycopeptide	28.1	221	502	361	2.60e-21	94.4
C103_contig_258_305	NCBI|WP_063856743.1|1|1|vanS-C|vanS-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-C|AMR|glycopeptide	26.9	253	502	361	3.51e-21	94.0
C103_contig_258_324	CARD|gb|ATC67679.1|ARO:3000838|arlR	28.6	112	252	219	1.54e-09	55.5
C103_contig_258_324	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	26.2	103	252	228	7.80e-09	53.5
C103_contig_258_324	CARD|gb|BAB36671.1|ARO:3000832|evgA	25.2	115	252	204	1.11e-06	47.0
C103_contig_258_328	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	40.3	221	229	219	3.44e-53	169
C103_contig_258_328	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	40.3	221	229	220	3.54e-53	169
C103_contig_258_328	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	40.3	221	229	220	5.01e-53	169
C103_contig_258_328	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	39.8	221	229	219	2.76e-52	167
C103_contig_258_328	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	40.3	221	229	220	8.04e-52	166
C103_contig_258_328	SARG|ZP_02848503	37.6	221	229	221	2.70e-47	154
C103_contig_258_328	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	38.4	229	229	231	1.61e-45	150
C103_contig_258_328	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	38.4	229	229	231	1.61e-45	150
C103_contig_258_328	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	39.4	221	229	228	5.90e-45	149
C103_contig_258_328	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	37.6	226	229	230	1.76e-44	147
C103_contig_258_331	SARG|L42544.gene.p01	31.0	654	973	651	3.75e-95	313
C103_contig_258_331	SARG|AAV80410	30.9	654	973	651	5.21e-94	310
C103_contig_258_331	SARG|YP_002850805	31.3	640	973	652	4.80e-86	289
C103_contig_258_331	SARG|AJ514254.gene.p01	29.9	632	973	640	1.84e-85	287
C103_contig_258_331	SARG|Q52360	30.3	643	973	641	3.61e-85	286
C103_contig_258_331	NCBI|WP_063856409.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	30.4	639	973	641	9.57e-85	285
C103_contig_258_331	SARG|P70882	30.2	643	973	641	9.57e-85	285
C103_contig_258_331	SARG|AAZ79478	30.4	644	973	657	1.39e-84	285
C103_contig_258_331	SARG|BAD46890	30.2	648	973	657	1.39e-84	285
C103_contig_258_331	SARG|ZP_02952732	30.9	640	973	652	1.71e-84	285
C103_contig_258_352	SARG|gb|ABA71733.1|ARO:3002972|vanTG	61.4	83	129	712	2.72e-28	107
C103_contig_258_352	NCBI|WP_063856752.1|1|1|vanT-G|vanT-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-G|AMR|glycopeptide	60.2	83	129	711	3.27e-27	103
C103_contig_258_352	NCBI|CZR78671.1|1|1|vanT-Cd|vanT-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-Cd|AMR|glycopeptide	55.4	83	129	712	4.13e-24	95.1
C103_contig_258_352	SARG|gi|498467693|ref|WP_010773049.1|	45.1	82	129	700	1.58e-12	62.0
C103_contig_258_352	SARG|JF802084.2.gene3.p01	42.7	82	129	700	4.01e-12	60.8
C103_contig_258_352	SARG|FJ872411.1.gene43.p01	41.5	82	129	702	3.51e-11	58.2
C103_contig_258_352	SARG|gi|748291566|ref|WP_039833224.1|	35.2	105	129	343	4.09e-11	57.8
C103_contig_258_352	SARG|AF155139.2.gene7.p01	54.3	46	129	343	5.59e-11	57.4
C103_contig_258_352	SARG|FJ349556.1.gene6.p01	54.3	46	129	343	7.63e-11	57.0
C103_contig_258_352	NCBI|WP_041219811.1|1|1|vanI|vanI|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-alanine--(R)-lactate_ligase_VanI|AMR|glycopeptide	36.5	104	129	346	7.67e-11	57.0
C103_contig_258_353	SARG|gb|ABA71729.1|ARO:3002959|vanYG1	74.2	194	271	279	3.19e-99	290
C103_contig_258_353	SARG|AAF71279	67.0	194	271	278	1.54e-84	253
C103_contig_258_353	SARG|gi|403023847|gb|EJY36064.1|	49.7	195	271	200	7.91e-61	190
C103_contig_258_353	SARG|gi|1036536100|emb|SAM71699.1|	42.7	255	271	268	1.58e-60	191
C103_contig_258_353	SARG|gi|452996227|gb|AGG19410.1|	49.5	198	271	252	2.77e-60	190
C103_contig_258_353	SARG|gi|488259314|ref|WP_002330522.1|	49.5	198	271	268	4.46e-60	190
C103_contig_258_353	SARG|KF823969.1.gene3.p01	49.5	198	271	268	4.46e-60	190
C103_contig_258_353	SARG|gi|403219412|emb|CCJ27774.1|	49.5	198	271	268	6.31e-60	190
C103_contig_258_353	SARG|gi|452996213|gb|AGG19398.1|	49.3	201	271	268	3.56e-59	188
C103_contig_258_353	SARG|gi|498515090|ref|WP_010815297.1|	49.3	201	271	268	3.56e-59	188
C103_contig_258_354	megares|MEG_7563|Drugs|Glycopeptide|VanB-type_resistance_protein|VANXB_4	48.5	66	91	246	5.81e-15	66.2
C103_contig_258_354	megares|MEG_7572|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_4	46.4	69	91	247	1.58e-14	65.1
C103_contig_258_354	megares|MEG_7571|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_3	47.0	66	91	248	4.31e-14	63.9
C103_contig_258_354	megares|MEG_7543|Drugs|Glycopeptide|VanG-type_accessory_protein|VANWG_1	43.5	69	91	281	2.86e-13	62.0
C103_contig_258_354	megares|MEG_7544|Drugs|Glycopeptide|VanG-type_accessory_protein|VANWG_1	43.5	69	91	281	2.86e-13	62.0
C103_contig_258_354	NCBI|WP_063856762.1|1|1|vanW-G|vanW-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_accessory_protein_VanW-G|AMR|glycopeptide	43.5	69	91	281	2.86e-13	62.0
C103_contig_258_354	NCBI|WP_021419095.1|1|1|vanW-G|vanW-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_accessory_protein_VanW-G|AMR|glycopeptide	43.5	69	91	281	2.86e-13	62.0
C103_contig_258_355	NCBI|WP_063856741.1|1|1|vanS-Pt|vanS-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt|AMR|glycopeptide	50.9	369	376	386	3.53e-116	342
C103_contig_258_355	megares|MEG_7488|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	50.9	369	376	386	3.53e-116	342
C103_contig_258_355	NCBI|WP_002305818.1|1|1|vanS-A|vanS-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-A|AMR|glycopeptide	49.7	372	376	384	7.57e-115	338
C103_contig_258_355	megares|MEG_7454|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	49.7	372	376	384	7.57e-115	338
C103_contig_258_355	megares|MEG_7487|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	49.6	369	376	386	7.44e-113	333
C103_contig_258_355	NCBI|WP_063856740.1|1|1|vanS-Pt2|vanS-Pt2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt2|AMR|glycopeptide	49.6	369	376	386	7.44e-113	333
C103_contig_258_355	megares|MEG_7486|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	49.7	372	376	382	9.26e-113	333
C103_contig_258_355	NCBI|WP_063856731.1|1|1|vanS-A|vanS-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-A|AMR|glycopeptide	49.7	372	376	382	9.26e-113	333
C103_contig_258_355	NCBI|WP_063856742.1|1|1|vanS-Pt|vanS-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt|AMR|glycopeptide	52.3	344	376	388	1.67e-109	325
C103_contig_258_355	megares|MEG_7489|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	52.3	344	376	388	1.67e-109	325
C103_contig_258_356	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	71.4	238	240	231	1.72e-122	346
C103_contig_258_356	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	70.2	238	240	231	2.00e-121	343
C103_contig_258_356	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	69.7	238	240	231	5.74e-121	342
C103_contig_258_356	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	68.9	238	240	231	1.64e-120	341
C103_contig_258_356	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	69.3	238	240	231	1.64e-120	341
C103_contig_258_356	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	61.3	238	240	232	2.53e-108	310
C103_contig_258_356	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	60.9	238	240	232	7.24e-108	309
C103_contig_258_356	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	58.0	238	240	233	1.68e-92	270
C103_contig_258_356	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	57.7	234	240	239	2.75e-90	265
C103_contig_258_356	NCBI|WP_063856722.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	56.7	238	240	232	3.08e-90	265
C103_contig_258_361	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	42.9	231	234	255	3.57e-57	181
C103_contig_258_361	SARG|gi|1001720867|ref|WP_061274204.1|	44.5	220	234	648	3.77e-50	172
C103_contig_258_361	SARG|gi|746253210|ref|WP_039301529.1|	44.5	220	234	648	7.26e-50	171
C103_contig_258_361	SARG|gi|736472622|ref|WP_034494292.1|	44.1	220	234	648	7.26e-50	171
C103_contig_258_361	SARG|gi|556495988|ref|WP_023343675.1|	43.9	221	234	646	1.37e-49	170
C103_contig_258_361	SARG|gi|495736522|ref|WP_008461101.1|	44.5	220	234	648	1.40e-49	170
C103_contig_258_361	SARG|gi|1016275448|gb|AMX06027.1|	44.1	220	234	646	1.90e-49	170
C103_contig_258_361	SARG|gi|823326845|ref|WP_047080664.1|	43.2	220	234	648	1.94e-49	170
C103_contig_258_361	SARG|gi|746243059|ref|WP_039291473.1|	44.5	220	234	648	2.69e-49	169
C103_contig_258_361	SARG|gi|1035670474|ref|WP_064517458.1|	43.6	220	234	648	2.69e-49	169
C103_contig_258_362	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	26.4	239	310	381	4.89e-17	79.7
C103_contig_258_362	megares|MEG_7504|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	26.4	239	310	381	4.89e-17	79.7
C103_contig_258_362	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	25.5	239	310	381	8.97e-17	79.0
C103_contig_258_362	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	25.5	239	310	381	8.97e-17	79.0
C103_contig_258_362	megares|MEG_7505|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	25.9	239	310	381	5.52e-16	76.6
C103_contig_258_362	NCBI|WP_063856730.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	25.9	239	310	381	5.52e-16	76.6
C103_contig_258_362	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	25.9	239	310	381	1.01e-15	75.9
C103_contig_258_362	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	25.9	239	310	381	1.01e-15	75.9
C103_contig_258_362	megares|MEG_7507|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	24.7	239	310	381	1.84e-15	75.1
C103_contig_258_362	NCBI|WP_063856738.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	24.7	239	310	381	1.84e-15	75.1
C103_contig_258_363	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	29.6	226	223	232	2.81e-35	124
C103_contig_258_363	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	29.6	226	223	232	2.81e-35	124
C103_contig_258_363	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	29.7	229	223	233	3.46e-33	118
C103_contig_258_363	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	30.0	220	223	219	6.82e-33	117
C103_contig_258_363	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	30.0	220	223	220	9.84e-33	117
C103_contig_258_363	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	30.0	217	223	219	1.90e-32	116
C103_contig_258_363	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	30.0	217	223	220	1.95e-32	116
C103_contig_258_363	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	30.0	217	223	220	2.75e-32	115
C103_contig_258_363	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	29.9	231	223	235	5.57e-32	115
C103_contig_258_363	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	32.3	220	223	228	7.20e-31	112
C103_contig_258_373	CARD|gb|BAB36671.1|ARO:3000832|evgA	29.6	115	532	204	2.53e-12	65.1
C103_contig_258_373	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	23.5	136	532	228	7.60e-07	49.3
C103_contig_258_373	CARD|gb|AAG05188.1|ARO:3005068|ParR	29.2	106	532	235	6.33e-06	46.6
C103_contig_258_377	SARG|gi|445996719|ref|WP_000074574.1|	30.3	228	513	309	2.32e-19	87.8
C103_contig_258_377	SARG|gi|445996724|ref|WP_000074579.1|	30.3	228	513	309	1.89e-18	85.1
C103_contig_258_377	SARG|gi|445996710|ref|WP_000074565.1|	30.3	228	513	309	1.89e-18	85.1
C103_contig_258_377	SARG|gi|445996722|ref|WP_000074577.1|	30.3	228	513	309	1.89e-18	85.1
C103_contig_258_377	SARG|gi|1043490477|ref|WP_065382463.1|	29.8	228	513	309	2.55e-18	84.7
C103_contig_258_377	SARG|gi|445996726|ref|WP_000074581.1|	29.8	228	513	309	2.55e-18	84.7
C103_contig_258_377	SARG|gi|884875933|emb|CKG93789.1|	30.3	228	513	309	2.55e-18	84.7
C103_contig_258_377	SARG|gi|445996723|ref|WP_000074578.1|	29.8	228	513	309	2.55e-18	84.7
C103_contig_258_377	SARG|gi|507054395|ref|WP_016125339.1|	29.8	228	513	309	2.55e-18	84.7
C103_contig_258_377	SARG|gi|445996729|ref|WP_000074584.1|	29.8	228	513	309	3.44e-18	84.3
C103_contig_258_381	SARG|gi|507035724|ref|WP_016107411.1|	32.8	241	296	309	1.40e-27	107
C103_contig_258_381	SARG|gi|445996698|ref|WP_000074553.1|	32.8	241	296	309	1.40e-27	107
C103_contig_258_381	SARG|gi|445996697|ref|WP_000074552.1|	32.8	241	296	309	1.94e-27	107
C103_contig_258_381	SARG|gb|AAC74000.1|ARO:3003950|msbA	33.9	248	296	582	3.78e-27	109
C103_contig_258_381	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	31.6	237	296	579	5.09e-27	109
C103_contig_258_381	SARG|gi|445996719|ref|WP_000074574.1|	32.0	241	296	309	5.19e-27	106
C103_contig_258_381	SARG|gi|445996709|ref|WP_000074564.1|	32.4	222	296	309	5.19e-27	106
C103_contig_258_381	SARG|gi|445996722|ref|WP_000074577.1|	32.4	241	296	309	5.19e-27	106
C103_contig_258_381	SARG|gi|445996723|ref|WP_000074578.1|	32.0	241	296	309	7.21e-27	105
C103_contig_258_381	SARG|gi|884875933|emb|CKG93789.1|	32.0	241	296	309	1.00e-26	105
C103_contig_258_382	SARG|gi|502669352|ref|WP_012905216.1|	30.6	206	282	648	2.46e-19	86.7
C103_contig_258_382	SARG|gi|803568669|ref|WP_046077412.1|	30.3	198	282	648	8.98e-18	82.0
C103_contig_258_382	SARG|gi|446110352|ref|WP_000188207.1|	30.3	198	282	648	8.98e-18	82.0
C103_contig_258_382	SARG|YP_002382193	30.3	198	282	648	8.98e-18	82.0
C103_contig_258_382	SARG|gi|803575554|ref|WP_046081557.1|	30.3	198	282	648	8.98e-18	82.0
C103_contig_258_382	SARG|gi|446110351|ref|WP_000188206.1|	30.3	198	282	648	8.98e-18	82.0
C103_contig_258_382	SARG|gi|1035670474|ref|WP_064517458.1|	29.0	217	282	648	1.21e-17	81.6
C103_contig_258_382	SARG|gi|1035717981|ref|WP_064557480.1|	29.0	217	282	648	1.21e-17	81.6
C103_contig_258_382	SARG|gi|736472622|ref|WP_034494292.1|	29.3	198	282	648	9.82e-17	79.0
C103_contig_258_382	SARG|gb|WP_104671188.1|ARO:3003948|efrA	28.5	239	282	575	1.25e-16	78.6
C103_contig_258_393	SARG|gi|686113687|ref|WP_031764317.1|	22.5	436	457	451	1.15e-17	84.0
C103_contig_258_417	SARG|gi|542061059|gb|ERI11611.1|	35.4	212	284	316	8.65e-27	105
C103_contig_258_417	SARG|gi|445996695|ref|WP_000074550.1|	33.3	216	284	309	3.97e-26	103
C103_contig_258_417	SARG|gi|507035724|ref|WP_016107411.1|	33.3	216	284	309	5.51e-26	103
C103_contig_258_417	SARG|gi|507055561|ref|WP_016126482.1|	33.0	218	284	309	5.51e-26	103
C103_contig_258_417	SARG|gi|445996719|ref|WP_000074574.1|	34.2	222	284	309	7.65e-26	102
C103_contig_258_417	SARG|gi|507050365|ref|WP_016121371.1|	32.6	218	284	309	1.06e-25	102
C103_contig_258_417	SARG|gi|445996698|ref|WP_000074553.1|	32.9	216	284	309	1.47e-25	102
C103_contig_258_417	SARG|gi|445996697|ref|WP_000074552.1|	33.3	216	284	309	1.47e-25	102
C103_contig_258_417	SARG|gi|445996696|ref|WP_000074551.1|	33.3	216	284	309	1.47e-25	102
C103_contig_258_417	SARG|gi|447195835|ref|WP_001273091.1|	33.8	210	284	306	1.94e-25	101
C103_contig_258_431	SARG|ZP_04528247	57.4	298	301	279	3.72e-113	327
C103_contig_258_431	SARG|ZP_03958019	57.3	293	301	317	7.23e-110	320
C103_contig_258_431	SARG|ZP_03984017	57.0	293	301	288	7.78e-110	319
C103_contig_258_431	SARG|ZP_04433866	57.0	293	301	288	1.56e-109	318
C103_contig_258_431	SARG|ZP_03949893	57.0	293	301	288	1.56e-109	318
C103_contig_258_431	SARG|YP_002929946	55.8	292	301	282	4.54e-105	306
C103_contig_258_431	SARG|ZP_03945515	54.8	294	301	291	1.23e-104	306
C103_contig_258_431	SARG|YP_002937728	53.6	302	301	289	3.79e-103	302
C103_contig_258_431	SARG|ZP_03938934	52.9	293	301	288	2.78e-100	295
C103_contig_258_431	SARG|ZP_03941859	52.6	293	301	288	1.12e-99	293
C103_contig_258_448	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	29.2	209	418	307	5.93e-21	91.7
C103_contig_258_448	SARG|gb|AGN74946|ARO:3003749|salA	34.3	175	418	541	1.43e-12	68.2
C103_contig_258_448	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.1	193	418	655	1.18e-11	65.5
C103_contig_258_448	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.1	193	418	655	1.18e-11	65.5
C103_contig_258_448	SARG|gi|445983931|ref|WP_000061786.1|	29.0	176	418	492	7.03e-11	62.8
C103_contig_258_448	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.5	193	418	655	8.51e-11	62.8
C103_contig_258_448	SARG|gi|445983932|ref|WP_000061787.1|	29.0	176	418	492	9.33e-11	62.4
C103_contig_258_448	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.5	193	418	655	1.13e-10	62.4
C103_contig_258_448	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.5	193	418	655	1.13e-10	62.4
C103_contig_258_448	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.5	193	418	655	1.13e-10	62.4
C103_contig_258_464	SARG|gi|1004359922|gb|AMP42228.1|	26.0	434	603	639	1.05e-28	120
C103_contig_258_464	SARG|AAY62597	26.0	435	603	639	5.89e-27	114
C103_contig_258_464	SARG|YP_594556	23.4	522	603	639	7.85e-27	114
C103_contig_258_464	SARG|gi|254967129|gb|ACT97610.1|	26.0	435	603	639	1.05e-26	114
C103_contig_258_464	SARG|AJ222769.gene.p01	26.0	435	603	639	1.05e-26	114
C103_contig_258_464	SARG|gi|168258996|gb|ACA23181.1|	26.0	435	603	639	1.05e-26	114
C103_contig_258_464	SARG|gi|1028100281|ref|WP_063856416.1|	26.0	435	603	639	1.05e-26	114
C103_contig_258_464	SARG|ACI02041	25.7	435	603	639	1.05e-26	114
C103_contig_258_464	SARG|ACA23195	26.0	435	603	639	1.05e-26	114
C103_contig_258_464	SARG|CAD13485	26.0	435	603	639	1.05e-26	114
C103_contig_258_469	NCBI|WP_011860980.1|1|1|blaAHM-1|blaAHM|hydrolase|2|CARBAPENEM|beta-lactam|subclass_B3-like_metallo-beta-lactamase_AHM-1|AMR|beta-lactam	25.5	247	793	304	2.38e-19	88.6
C103_contig_258_471	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	24.9	301	476	370	4.97e-25	105
C103_contig_258_471	NCBI|WP_002382867.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	25.6	234	476	447	9.28e-19	87.4
C103_contig_258_471	NCBI|WP_012579101.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	25.6	234	476	447	9.28e-19	87.4
C103_contig_258_471	NCBI|WP_063856739.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	25.6	234	476	447	9.28e-19	87.4
C103_contig_258_471	NCBI|WP_063856751.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	25.9	228	476	454	1.72e-18	86.7
C103_contig_258_471	NCBI|WP_063856737.1|1|1|vanS-B-Delta|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|VanB-type_glycopeptide_resistance_histidine_kinase_VanS-B-Delta|AMR|glycopeptide	25.2	234	476	441	6.96e-16	78.6
C103_contig_258_471	CARD|gb|CYF42523.1|ARO:3004047|kdpD	23.6	237	476	885	3.48e-12	67.8
C103_contig_258_472	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	44.4	225	230	232	2.31e-62	193
C103_contig_258_472	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	44.6	224	230	231	1.46e-60	189
C103_contig_258_472	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	44.4	225	230	228	2.67e-60	188
C103_contig_258_472	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	45.9	229	230	233	2.50e-59	186
C103_contig_258_472	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	43.5	232	230	232	4.87e-59	185
C103_contig_258_472	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	43.5	230	230	231	6.68e-59	184
C103_contig_258_472	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	45.0	231	230	235	1.07e-58	184
C103_contig_258_472	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	44.4	223	230	229	1.26e-58	184
C103_contig_258_472	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	43.1	232	230	232	1.38e-58	184
C103_contig_258_472	CARD|gb|ATC67679.1|ARO:3000838|arlR	42.8	222	230	219	2.64e-58	182
C103_contig_258_487	SARG|gb|AAK76136.1|ARO:3000025|patB	31.6	605	637	588	2.49e-92	296
C103_contig_258_487	SARG|gb|AYV52072.1|ARO:3002882|lmrD	33.1	544	637	664	1.96e-87	285
C103_contig_258_487	SARG|gi|497748188|ref|WP_010062372.1|	30.6	605	637	605	5.28e-78	258
C103_contig_258_487	SARG|gi|695865802|ref|WP_032778631.1|	30.4	605	637	605	5.44e-77	256
C103_contig_258_487	SARG|gi|664180077|ref|WP_030714054.1|	30.6	605	637	605	7.59e-77	255
C103_contig_258_487	SARG|gi|663330365|ref|WP_030329892.1|	30.1	605	637	607	7.94e-77	255
C103_contig_258_487	SARG|gi|695887424|ref|WP_032788534.1|	30.4	605	637	605	1.48e-76	254
C103_contig_258_487	SARG|gi|764446018|ref|WP_044369325.1|	30.2	605	637	605	2.06e-76	254
C103_contig_258_487	SARG|gi|663155409|ref|WP_030194633.1|	29.9	605	637	605	2.06e-76	254
C103_contig_258_487	SARG|gi|664538723|ref|WP_031054357.1|	29.9	605	637	605	2.06e-76	254
C103_contig_258_488	SARG|gb|WP_104671188.1|ARO:3003948|efrA	34.5	563	586	575	2.79e-107	333
C103_contig_258_488	SARG|gb|AAK76137.1|ARO:3000024|patA	33.5	522	586	564	1.14e-94	300
C103_contig_258_488	SARG|gb|AAK76136.1|ARO:3000025|patB	30.2	487	586	588	2.87e-65	223
C103_contig_258_488	SARG|gi|1045390184|ref|WP_065479071.1|	29.2	537	586	605	7.72e-63	216
C103_contig_258_488	SARG|gi|695842130|ref|WP_032755430.1|	29.6	537	586	603	5.31e-62	214
C103_contig_258_488	SARG|gb|AYV52072.1|ARO:3002882|lmrD	28.3	487	586	664	8.09e-62	215
C103_contig_258_488	SARG|gi|764446018|ref|WP_044369325.1|	28.9	537	586	605	2.83e-61	212
C103_contig_258_488	SARG|gi|695865802|ref|WP_032778631.1|	28.7	537	586	605	3.92e-61	212
C103_contig_258_488	SARG|gi|664180077|ref|WP_030714054.1|	28.7	537	586	605	5.44e-61	211
C103_contig_258_488	SARG|gi|664170108|ref|WP_030704355.1|	28.7	537	586	603	1.01e-60	211
C103_contig_258_493	CARD|gb|AAC73788.1|ARO:3003841|kdpE	30.7	228	226	225	6.71e-32	115
C103_contig_258_493	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	30.7	225	226	225	2.63e-31	113
C103_contig_258_493	CARD|gb|SIP52035.1|ARO:3004054|Paer_CpxR	29.1	206	226	225	3.19e-23	92.4
C103_contig_258_493	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	30.1	226	226	228	6.88e-22	89.0
C103_contig_258_493	CARD|gb|AAG05188.1|ARO:3005068|ParR	28.4	225	226	235	1.10e-21	88.6
C103_contig_258_494	NCBI|WP_063856734.1|1|1|vanS-E|vanS-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-E|AMR|glycopeptide	22.1	222	259	357	3.32e-10	58.5
C103_contig_258_494	megares|MEG_7511|Drugs|Glycopeptide|VanE-type_regulator|VANSE_1	22.1	222	259	357	3.32e-10	58.5
C103_contig_258_495	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	44.6	224	224	255	6.63e-63	195
C103_contig_258_495	SARG|gi|736472622|ref|WP_034494292.1|	44.8	221	224	648	9.68e-57	189
C103_contig_258_495	SARG|gi|1035706844|ref|WP_064548272.1|	45.2	221	224	648	9.68e-57	189
C103_contig_258_495	SARG|Q83LR7	45.9	220	224	648	1.88e-56	188
C103_contig_258_495	SARG|gi|647325472|ref|WP_025760953.1|	45.9	220	224	648	1.88e-56	188
C103_contig_258_495	SARG|gi|647323678|ref|WP_025760497.1|	45.9	220	224	648	1.88e-56	188
C103_contig_258_495	SARG|gi|1035670474|ref|WP_064517458.1|	44.3	221	224	648	5.07e-56	187
C103_contig_258_495	SARG|gi|1035717981|ref|WP_064557480.1|	44.3	221	224	648	5.07e-56	187
C103_contig_258_495	SARG|gi|446110305|ref|WP_000188160.1|	45.5	220	224	648	7.06e-56	187
C103_contig_258_495	SARG|gi|391288090|gb|EIQ46599.1|	45.0	220	224	645	3.55e-55	185
C103_contig_258_511	SARG|gi|686123390|ref|WP_031769354.1|	26.7	435	451	451	2.80e-42	154
C103_contig_258_511	SARG|gi|686334333|ref|WP_031881350.1|	26.4	435	451	451	7.43e-42	153
C103_contig_258_511	SARG|gi|686294396|ref|WP_031862836.1|	26.4	435	451	451	7.43e-42	153
C103_contig_258_511	SARG|gi|686390606|ref|WP_031905637.1|	26.4	435	451	451	7.43e-42	153
C103_contig_258_511	SARG|Q2G140	26.4	435	451	451	7.43e-42	153
C103_contig_258_511	SARG|gi|727742662|ref|WP_033858866.1|	26.4	435	451	451	7.43e-42	153
C103_contig_258_511	SARG|gi|487138435|ref|WP_001629863.1|	26.7	435	451	451	7.43e-42	153
C103_contig_258_511	SARG|gi|486215009|ref|WP_001556470.1|	26.4	435	451	451	7.43e-42	153
C103_contig_258_511	SARG|gi|757671144|ref|WP_042903632.1|	26.4	435	451	451	1.03e-41	152
C103_contig_258_511	SARG|gi|763462741|ref|WP_044292157.1|	26.2	435	451	451	1.03e-41	152
C103_contig_258_512	SARG|gi|313638554|gb|EFS03703.1|	26.2	446	447	453	7.47e-36	136
C103_contig_258_512	SARG|gi|313614636|gb|EFR88215.1|	25.8	453	447	453	6.41e-34	131
C103_contig_258_512	SARG|gb|CAE00499.1|ARO:3003835|cdeA	23.0	427	447	441	9.82e-28	113
C103_contig_258_553	SARG|gi|1001720867|ref|WP_061274204.1|	42.1	221	233	648	1.82e-57	191
C103_contig_258_553	SARG|gi|495736522|ref|WP_008461101.1|	41.6	221	233	648	4.91e-57	190
C103_contig_258_553	SARG|gi|746253210|ref|WP_039301529.1|	41.6	221	233	648	4.91e-57	190
C103_contig_258_553	SARG|gi|1035670474|ref|WP_064517458.1|	41.3	230	233	648	9.53e-57	189
C103_contig_258_553	SARG|gi|746243059|ref|WP_039291473.1|	39.7	234	233	648	2.57e-56	188
C103_contig_258_553	SARG|gi|736472622|ref|WP_034494292.1|	40.9	230	233	648	3.59e-56	188
C103_contig_258_553	SARG|gi|1035717981|ref|WP_064557480.1|	42.1	221	233	648	4.99e-56	187
C103_contig_258_553	SARG|Q83LR7	40.7	221	233	648	1.35e-55	186
C103_contig_258_553	SARG|gi|647325472|ref|WP_025760953.1|	40.7	221	233	648	1.35e-55	186
C103_contig_258_553	SARG|gi|647323678|ref|WP_025760497.1|	40.7	221	233	648	1.35e-55	186
C103_contig_258_568	SARG|gb|AML99881.1|ARO:3001327|mdtK	20.1	418	441	474	5.88e-06	47.4
C103_contig_258_595	SARG|gi|1045390184|ref|WP_065479071.1|	38.9	239	610	605	1.77e-43	163
C103_contig_258_595	SARG|gi|662754041|ref|WP_030125200.1|	37.7	239	610	601	2.01e-42	160
C103_contig_258_595	SARG|gi|664100597|ref|WP_030638327.1|	37.7	239	610	601	2.01e-42	160
C103_contig_258_595	SARG|gi|505389066|ref|WP_015576168.1|	37.7	239	610	601	2.01e-42	160
C103_contig_258_595	SARG|gi|503923650|ref|WP_014157644.1|	37.7	239	610	601	2.01e-42	160
C103_contig_258_595	SARG|gi|695865802|ref|WP_032778631.1|	38.1	239	610	605	2.11e-42	160
C103_contig_258_595	SARG|gi|921231571|ref|WP_053176464.1|	37.7	239	610	620	2.49e-42	160
C103_contig_258_595	SARG|gi|664352659|ref|WP_030880307.1|	37.7	239	610	601	2.74e-42	160
C103_contig_258_595	SARG|gi|639892676|ref|WP_024755698.1|	36.9	260	610	631	2.79e-42	160
C103_contig_258_595	SARG|gi|917172177|ref|WP_051778889.1|	37.7	239	610	620	3.38e-42	160
C103_contig_258_596	SARG|gb|AAC74000.1|ARO:3003950|msbA	35.5	301	624	582	3.26e-50	182
C103_contig_258_596	SARG|gi|663350985|ref|WP_030349761.1|	32.6	344	624	613	5.86e-48	176
C103_contig_258_596	SARG|gi|662129758|ref|WP_030081404.1|	31.7	344	624	605	8.85e-47	173
C103_contig_258_596	SARG|gi|947982677|ref|WP_056642336.1|	31.8	346	624	626	1.16e-46	173
C103_contig_258_596	SARG|gi|664085850|ref|WP_030624018.1|	31.7	344	624	605	1.21e-46	172
C103_contig_258_596	SARG|gi|695865802|ref|WP_032778631.1|	31.7	344	624	605	1.21e-46	172
C103_contig_258_596	SARG|gi|639892676|ref|WP_024755698.1|	31.8	346	624	631	1.23e-46	173
C103_contig_258_596	SARG|gi|953808775|ref|WP_058042812.1|	33.0	349	624	608	1.26e-46	172
C103_contig_258_596	SARG|gi|664244930|ref|WP_030776974.1|	31.1	350	624	601	1.57e-46	172
C103_contig_258_596	SARG|gi|943896259|ref|WP_055534530.1|	31.4	350	624	601	2.15e-46	172
C103_contig_258_735	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	46.9	96	117	231	1.09e-22	87.4
C103_contig_258_737	SARG|gi|542061059|gb|ERI11611.1|	40.5	222	292	316	5.13e-44	151
C103_contig_258_737	SARG|ABB80128	39.8	211	292	306	9.25e-42	145
C103_contig_258_737	SARG|P42332	39.3	211	292	306	1.39e-40	142
C103_contig_258_737	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	39.3	211	292	306	1.39e-40	142
C103_contig_258_737	SARG|gi|510143239|gb|AGN36970.1|	39.3	211	292	313	1.64e-40	142
C103_contig_258_737	SARG|gi|500194536|ref|WP_011867743.1|	38.9	211	292	306	2.75e-40	141
C103_contig_258_737	SARG|gi|447195835|ref|WP_001273091.1|	39.8	211	292	306	2.75e-40	141
C103_contig_258_737	SARG|ZP_04081918	39.3	211	292	306	7.58e-40	140
C103_contig_258_737	SARG|gi|446026113|ref|WP_000103968.1|	37.9	211	292	306	7.58e-40	140
C103_contig_258_737	SARG|gi|447195836|ref|WP_001273092.1|	39.3	211	292	306	7.58e-40	140
C103_contig_258_738	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	28.4	264	392	365	1.24e-14	73.6
C103_contig_258_738	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	27.1	262	392	370	3.08e-14	72.4
C103_contig_258_738	CARD|gb|ADM92606.1|ARO:3000549|adeS	24.6	268	392	361	5.70e-10	59.3
C103_contig_258_739	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	41.1	224	225	231	3.43e-52	167
C103_contig_258_739	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	36.2	232	225	235	1.97e-49	160
C103_contig_258_739	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	41.2	228	225	229	1.87e-48	157
C103_contig_258_739	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	39.3	224	225	232	5.76e-48	156
C103_contig_258_739	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	38.2	228	225	231	8.90e-47	153
C103_contig_258_739	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	37.7	228	225	231	2.51e-46	152
C103_contig_258_739	NCBI|WP_063856722.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	36.8	231	225	232	3.65e-46	152
C103_contig_258_739	CARD|gb|ATC67679.1|ARO:3000838|arlR	38.1	218	225	219	5.04e-46	151
C103_contig_258_739	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	36.5	230	225	233	7.50e-46	151
C103_contig_258_739	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	36.2	229	225	231	2.24e-44	147
C103_contig_258_748	SARG|gb|AAY32951.1|ARO:3002837|lnuC	60.4	164	166	164	1.05e-70	209
C103_contig_258_748	SARG|gb|ABR14060.1|ARO:3002838|lnuD	61.6	164	166	164	1.49e-70	209
C103_contig_258_748	SARG|gb|ACS83559.1|ARO:3004601|LnuP	54.9	164	166	166	4.75e-65	195
C103_contig_258_748	megares|MEG_3621|Drugs|MLS|Lincosamide_nucleotidyltransferases|LNUP_1	56.0	159	166	166	6.74e-65	195
C103_contig_258_749	NCBI|AKC61310.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	33.3	75	139	552	4.60e-11	58.2
C103_contig_258_749	NCBI|AJP12342.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	35.1	74	139	550	1.16e-10	57.0
C103_contig_258_749	SARG|gb|MBW0770001.1|ARO:3007026|salB	32.1	78	139	541	2.53e-09	53.1
C103_contig_258_749	CARD|gb|BAB80490.1|ARO:3007644|Cper_cplR	28.4	74	139	568	2.55e-09	53.1
C103_contig_258_749	SARG|gb|AGN74946|ARO:3003749|salA	28.8	80	139	541	6.38e-09	52.0
C103_contig_258_749	SARG|gb|WP_096809342.1|ARO:3007029|salE	31.5	89	139	543	2.19e-08	50.4
C103_contig_258_749	SARG|GQ205627.2.gene1.p01	25.4	114	139	525	5.48e-08	49.3
C103_contig_258_749	NCBI|WP_000420313.1|1|1|msr(D)|msr(D)|target_protection|2|AZITHROMYCIN/ERYTHROMYCIN/STREPTOGRAMIN_B|MACROLIDE/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_Msr(D)|AMR|multidrug	27.4	73	139	487	1.17e-06	45.4
C103_contig_258_749	NCBI|WP_000420317.1|1|1|msr(D)|msr(D)|target_protection|2|AZITHROMYCIN/ERYTHROMYCIN/STREPTOGRAMIN_B|MACROLIDE/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_Msr(D)|AMR|multidrug	27.4	73	139	487	1.17e-06	45.4
C103_contig_258_749	SARG|DAC81085.1	25.3	75	139	486	3.99e-06	43.9
C103_contig_258_750	SARG|gb|ABX00624.1|ARO:3002881|lmrC	27.5	233	238	550	9.52e-11	60.1
C103_contig_258_750	SARG|FR772051.1.gene9.p01	40.7	59	238	524	4.73e-08	52.0
C103_contig_258_750	SARG|gb|AHB37625.1|ARO:3004715|vga(E)	39.0	59	238	524	1.54e-07	50.4
C103_contig_258_750	SARG|gb|AEO25219.1|ARO:3004651|lin	36.8	87	238	523	3.71e-07	49.3
C103_contig_258_750	SARG|GQ205627.2.gene1.p01	30.4	102	238	525	3.71e-07	49.3
C103_contig_258_750	SARG|DAC81085.1	39.0	59	238	486	8.71e-07	48.1
C103_contig_258_750	SARG|U82085.gene.p01	39.0	59	238	552	9.10e-07	48.1
C103_contig_258_750	SARG|AAG08983	33.9	59	238	524	1.20e-06	47.8
C103_contig_258_750	NCBI|WP_032492560.1|1|1|vga(A)|vga(A)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(A)|AMR|lincosamide	30.5	59	238	522	5.17e-06	45.8
C103_contig_258_750	SARG|DQ823382.1.gene1.p01	30.5	59	238	522	5.17e-06	45.8
C103_contig_258_751	SARG|gb|AVI44920.1|ARO:3004470|poxtA	35.1	77	140	542	3.58e-07	47.0
C103_contig_258_751	NCBI|WP_209691075.1|1|1|poxtA2|poxtA|target_protection|2|CHLORAMPHENICOL/FLORFENICOL/LINEZOLID|OXAZOLIDINONE/PHENICOL|ABC-F_type_ribosomal_protection_protein_PoxtA2|AMR|multidrug	35.1	77	140	544	3.58e-07	47.0
C103_contig_258_796	CARD|gb|WKR28567.1|ARO:3007678|IreK	37.5	80	116	718	3.32e-09	52.0
C103_contig_258_797	SARG|ABV82120	98.4	315	316	639	6.21e-220	612
C103_contig_258_797	SARG|ZP_03989103	98.1	315	316	639	2.52e-219	610
C103_contig_258_797	SARG|ABV82118	96.8	315	316	639	6.36e-215	599
C103_contig_258_797	SARG|AJ295238.gene.p01	94.6	315	316	639	1.60e-210	588
C103_contig_258_797	megares|MEG_7171|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	93.3	315	316	639	3.03e-208	582
C103_contig_258_797	SARG|FN594949.1.gene24.p01	70.6	309	316	640	2.34e-152	440
C103_contig_258_797	NCBI|WP_003454408.1|1|1|tet(44)|tet(44)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(44)|AMR|tetracycline	70.6	309	316	640	9.39e-152	439
C103_contig_258_797	megares|MEG_7166|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	67.9	315	316	639	6.72e-149	431
C103_contig_258_797	megares|MEG_7164|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	67.9	315	316	639	6.72e-149	431
C103_contig_258_797	megares|MEG_7165|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	67.3	315	316	639	2.70e-148	430
C103_contig_258_798	SARG|ZP_03989103	100	297	298	639	2.66e-216	602
C103_contig_258_798	SARG|ABV82120	100	297	298	639	2.66e-216	602
C103_contig_258_798	SARG|ABV82118	99.0	297	298	639	1.01e-213	595
C103_contig_258_798	SARG|AJ295238.gene.p01	82.4	296	298	639	4.10e-181	513
C103_contig_258_798	SARG|ABF69686	82.1	296	298	639	6.67e-180	509
C103_contig_258_798	megares|MEG_7171|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	81.8	296	298	639	6.67e-180	509
C103_contig_258_798	megares|MEG_7166|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	81.8	296	298	639	6.67e-180	509
C103_contig_258_798	SARG|ABG81258	81.8	296	298	639	1.90e-179	508
C103_contig_258_798	NCBI|WP_013646121.1|1|1|tet(O/W/32/O)|tet(O/W/32/O)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_mosaic_protein_Tet(O/W/32/O)|AMR|tetracycline	81.8	296	298	639	5.41e-179	507
C103_contig_258_798	NCBI|WP_204313011.1|1|1|tet(W/32/O)|tet(W/32/O)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_mosaic_protein_Tet(W/32/O)|AMR|tetracycline	81.8	296	298	639	5.41e-179	507
C103_contig_1385_3	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	26.0	242	1049	381	1.79e-13	72.4
C103_contig_1385_3	megares|MEG_7504|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	26.0	242	1049	381	1.79e-13	72.4
C103_contig_1385_3	megares|MEG_7505|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	26.5	238	1049	381	7.46e-13	70.5
C103_contig_1385_3	NCBI|WP_063856730.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	26.5	238	1049	381	7.46e-13	70.5
C103_contig_1385_3	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	26.5	238	1049	381	1.32e-12	69.7
C103_contig_1385_3	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	26.5	238	1049	381	1.32e-12	69.7
C103_contig_1385_3	megares|MEG_7507|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	26.5	238	1049	381	7.29e-12	67.4
C103_contig_1385_3	NCBI|WP_063856738.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	26.5	238	1049	381	7.29e-12	67.4
C103_contig_1385_3	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	25.6	238	1049	381	9.69e-12	67.0
C103_contig_1385_3	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	25.6	238	1049	381	9.69e-12	67.0
C103_contig_1385_6	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	27.5	236	238	307	4.04e-18	80.5
C103_contig_1385_6	NCBI|WP_002294513.1|1|1|lsa(E)|lsa(E)|target_protection|2|LINCOSAMIDE/STREPTOGRAMIN|LINCOSAMIDE/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_Lsa(E)|AMR|multidrug	27.1	192	238	494	1.20e-16	77.4
C103_contig_1385_6	megares|MEG_4322|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.8	225	238	655	1.53e-15	74.3
C103_contig_1385_6	megares|MEG_4321|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	28.9	225	238	655	1.26e-14	71.6
C103_contig_1385_6	megares|MEG_4317|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	28.9	225	238	655	1.26e-14	71.6
C103_contig_1385_6	megares|MEG_4314|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	28.9	225	238	655	1.26e-14	71.6
C103_contig_1385_6	megares|MEG_4323|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	28.9	225	238	655	1.26e-14	71.6
C103_contig_1385_6	megares|MEG_4319|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	28.9	225	238	655	1.26e-14	71.6
C103_contig_1385_6	megares|MEG_4311|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	28.9	225	238	655	1.26e-14	71.6
C103_contig_1385_6	megares|MEG_4305|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	28.9	225	238	655	1.26e-14	71.6
C103_contig_1385_15	NCBI|WP_063856729.1|1|1|vanR-O|vanR-O|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-O|AMR|glycopeptide	38.3	201	225	233	4.72e-47	154
C103_contig_1385_15	CARD|gb|AAG06465.1|ARO:3005063|cprR	35.3	221	225	223	1.57e-39	134
C103_contig_1385_15	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	33.8	222	225	219	1.24e-37	129
C103_contig_1385_15	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	36.1	230	225	232	3.46e-37	129
C103_contig_1385_15	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	36.1	230	225	232	3.46e-37	129
C103_contig_1385_15	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	33.8	222	225	219	3.47e-37	128
C103_contig_1385_15	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	33.8	222	225	220	3.57e-37	128
C103_contig_1385_15	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	33.8	222	225	220	5.03e-37	128
C103_contig_1385_15	SARG|ZP_02848503	34.8	224	225	221	7.28e-37	127
C103_contig_1385_15	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	33.3	222	225	220	1.11e-35	124
C103_contig_1385_16	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	30.6	229	406	364	6.66e-17	80.5
C103_contig_1385_16	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	30.6	229	406	364	6.66e-17	80.5
C103_contig_1385_16	megares|MEG_7521|Drugs|Glycopeptide|VanN-type_regulator|VANSN_1	27.1	269	406	364	1.73e-15	76.3
C103_contig_1385_16	NCBI|WP_063856749.1|1|1|vanS-N|vanS-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-N|AMR|glycopeptide	27.1	269	406	364	1.73e-15	76.3
C103_contig_1385_16	CARD|gb|ADM92606.1|ARO:3000549|adeS	29.1	251	406	361	2.28e-15	75.9
C103_contig_1385_28	SARG|gb|AAK76137.1|ARO:3000024|patA	24.6	272	519	564	2.44e-12	68.2
C103_contig_1385_28	SARG|gi|748767925|ref|WP_040019608.1|	25.7	210	519	623	1.79e-07	52.8
C103_contig_1385_28	SARG|gi|926400371|ref|WP_053728483.1|	25.8	209	519	603	3.07e-07	52.0
C103_contig_1385_28	SARG|gi|497748188|ref|WP_010062372.1|	23.4	209	519	605	3.07e-07	52.0
C103_contig_1385_28	SARG|gi|860594225|ref|WP_048475168.1|	23.5	217	519	620	3.11e-07	52.0
C103_contig_1385_28	SARG|gi|943938624|ref|WP_055567802.1|	23.9	209	519	602	4.05e-07	51.6
C103_contig_1385_28	SARG|gi|1033151784|ref|WP_064457526.1|	24.8	214	519	614	4.08e-07	51.6
C103_contig_1385_28	SARG|gi|664304639|ref|WP_030834011.1|	24.8	214	519	614	4.08e-07	51.6
C103_contig_1385_28	SARG|gi|1011069317|ref|WP_062010695.1|	24.8	214	519	614	4.08e-07	51.6
C103_contig_1385_28	SARG|gi|664170108|ref|WP_030704355.1|	23.9	209	519	603	5.34e-07	51.2
C103_contig_1385_34	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	28.6	133	671	231	1.44e-10	60.8
C103_contig_1385_34	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	30.1	123	671	231	2.10e-09	57.4
C103_contig_1385_34	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	32.4	105	671	232	1.27e-08	55.1
C103_contig_1385_34	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	26.5	113	671	220	6.52e-08	52.8
C103_contig_1385_34	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	25.7	113	671	219	8.68e-08	52.4
C103_contig_1385_34	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	25.7	113	671	219	8.68e-08	52.4
C103_contig_1385_34	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	25.7	113	671	220	8.78e-08	52.4
C103_contig_1385_34	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	24.8	113	671	220	2.88e-07	50.8
C103_contig_1385_39	CARD|gb|AAC75429.1|ARO:3000833|evgS	32.4	374	1298	1197	1.14e-50	195
C103_contig_1385_39	CARD|gb|AAD51347.1|ARO:3003067|smeS	28.4	208	1298	467	1.00e-15	80.5
C103_contig_1385_74	SARG|gb|AAV85982.1|ARO:3000535|macB	33.3	225	575	644	2.09e-26	112
C103_contig_1385_74	SARG|gi|922960663|ref|WP_053388845.1|	31.7	221	575	648	6.67e-26	111
C103_contig_1385_74	SARG|gi|757799695|ref|WP_043016897.1|	31.7	221	575	648	8.88e-26	110
C103_contig_1385_74	SARG|gi|1045891604|ref|WP_065554100.1|	31.7	221	575	648	8.88e-26	110
C103_contig_1385_74	SARG|gi|507082903|ref|WP_016153652.1|	31.7	221	575	648	8.88e-26	110
C103_contig_1385_74	SARG|gi|740856590|ref|WP_038641842.1|	31.7	221	575	648	8.88e-26	110
C103_contig_1385_74	SARG|gi|507086196|ref|WP_016156937.1|	31.7	221	575	648	8.88e-26	110
C103_contig_1385_74	SARG|gi|494938585|ref|WP_007664615.1|	32.1	224	575	647	1.18e-25	110
C103_contig_1385_74	SARG|gi|835233765|ref|WP_047410073.1|	31.7	221	575	648	1.18e-25	110
C103_contig_1385_74	SARG|gi|754951242|ref|WP_042307417.1|	31.7	221	575	648	1.18e-25	110
C103_contig_1385_87	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	24.5	237	429	359	1.44e-15	76.6
C103_contig_1385_87	CARD|gb|AEX49906.1|ARO:3003583|basS	24.9	233	429	477	3.27e-13	70.1
C103_contig_1385_87	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	22.0	227	429	364	1.63e-12	67.4
C103_contig_1385_87	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	22.0	227	429	364	1.63e-12	67.4
C103_contig_1385_88	SARG|ZP_02848503	35.3	221	229	221	1.53e-43	145
C103_contig_1385_88	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	34.1	232	229	232	1.03e-40	138
C103_contig_1385_88	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	36.0	225	229	229	3.75e-40	136
C103_contig_1385_88	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	31.9	226	229	232	2.39e-35	124
C103_contig_1385_88	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	31.9	226	229	232	2.39e-35	124
C103_contig_1385_88	CARD|gb|AAG05188.1|ARO:3005068|ParR	32.7	223	229	235	4.34e-33	118
C103_contig_1385_88	CARD|gb|AAD51348.1|ARO:3003066|smeR	34.1	220	229	229	4.08e-32	115
C103_contig_1385_88	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	31.2	234	229	235	2.59e-31	114
C103_contig_1385_88	NCBI|WP_011029105.1|1|1|vanR-Sc|vanR-Sc|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-Sc|AMR|glycopeptide	32.6	218	229	231	1.14e-27	104
C103_contig_1385_88	CARD|gb|ADM92605.1|ARO:3000553|adeR	31.3	224	229	247	2.27e-27	103
C103_contig_1385_102	SARG|gi|445996723|ref|WP_000074578.1|	30.8	221	504	309	9.52e-16	77.0
C103_contig_1385_102	SARG|gi|445996722|ref|WP_000074577.1|	30.8	221	504	309	9.52e-16	77.0
C103_contig_1385_102	SARG|gi|445996724|ref|WP_000074579.1|	30.3	221	504	309	2.32e-15	75.9
C103_contig_1385_102	SARG|gi|1043490477|ref|WP_065382463.1|	30.3	221	504	309	2.32e-15	75.9
C103_contig_1385_102	SARG|gi|445996726|ref|WP_000074581.1|	30.3	221	504	309	2.32e-15	75.9
C103_contig_1385_102	SARG|gi|447057509|ref|WP_001134765.1|	29.9	221	504	309	2.32e-15	75.9
C103_contig_1385_102	SARG|gi|507054395|ref|WP_016125339.1|	30.3	221	504	309	2.32e-15	75.9
C103_contig_1385_102	SARG|gi|542061059|gb|ERI11611.1|	29.3	229	504	316	2.50e-15	75.9
C103_contig_1385_102	SARG|gi|507035724|ref|WP_016107411.1|	29.9	221	504	309	3.11e-15	75.5
C103_contig_1385_102	SARG|gi|445996698|ref|WP_000074553.1|	29.9	221	504	309	3.11e-15	75.5
C103_contig_1385_112	CARD|gb|AAC75429.1|ARO:3000833|evgS	32.4	389	687	1197	4.20e-45	172
C103_contig_1385_112	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	25.2	222	687	359	8.77e-21	93.6
C103_contig_1385_112	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	25.1	223	687	364	2.38e-19	89.4
C103_contig_1385_112	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	25.1	223	687	364	2.38e-19	89.4
C103_contig_1385_112	CARD|gb|ADM92606.1|ARO:3000549|adeS	26.7	221	687	361	3.36e-17	82.8
C103_contig_1385_112	CARD|gb|AEX49906.1|ARO:3003583|basS	26.1	234	687	477	8.77e-14	73.2
C103_contig_1385_112	CARD|gb|ATC67679.1|ARO:3000838|arlR	32.5	123	687	219	1.12e-11	63.9
C103_contig_1385_112	CARD|gb|AAD51347.1|ARO:3003067|smeS	22.7	220	687	467	6.65e-10	60.8
C103_contig_1385_112	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	30.8	107	687	231	1.74e-08	54.7
C103_contig_1385_112	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	30.8	107	687	232	1.39e-07	52.0
C103_contig_399_4	SARG|DQ212986.1.gene3.p01	41.4	70	91	75	6.11e-16	65.1
C103_contig_399_37	CARD|gb|ATC67679.1|ARO:3000838|arlR	24.4	127	510	219	1.14e-10	60.5
C103_contig_399_37	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	26.1	111	510	228	3.73e-08	53.1
C103_contig_399_47	CARD|gb|BAB36671.1|ARO:3000832|evgA	27.7	119	246	204	1.86e-10	57.8
C103_contig_399_47	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	31.9	113	246	228	6.23e-10	56.6
C103_contig_399_50	SARG|gi|542061059|gb|ERI11611.1|	36.2	221	238	316	5.50e-44	149
C103_contig_399_50	NCBI|QHA94808.1|1|1|narA|narA||1|MADURAMICIN/NARASIN/SALINOMYCIN|IONOPHORE|ionophore_ABC_transporter_ATP-binding_subunit_NarA|AMR|ionophore	34.5	220	238	293	2.45e-43	147
C103_contig_399_50	SARG|gi|500194536|ref|WP_011867743.1|	35.4	212	238	306	1.21e-39	137
C103_contig_399_50	CARD|gb|BAB80490.1|ARO:3007644|Cper_cplR	37.9	58	238	568	5.11e-07	48.9
C103_contig_399_82	megares|MEG_1680|Drugs|MLS|23S_rRNA_methyltransferases|CFR_1	60.7	61	63	416	2.96e-22	86.3
C103_contig_399_127	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	31.1	225	237	307	1.68e-27	105
C103_contig_399_127	SARG|gi|542061059|gb|ERI11611.1|	28.6	227	237	316	2.77e-23	94.7
C103_contig_399_127	SARG|ZP_04081918	28.8	226	237	306	3.33e-23	94.4
C103_contig_399_127	SARG|gi|447195836|ref|WP_001273092.1|	28.8	226	237	306	3.33e-23	94.4
C103_contig_399_127	SARG|gi|447195835|ref|WP_001273091.1|	28.8	226	237	306	4.62e-23	94.0
C103_contig_399_127	NCBI|QHA94808.1|1|1|narA|narA||1|MADURAMICIN/NARASIN/SALINOMYCIN|IONOPHORE|ionophore_ABC_transporter_ATP-binding_subunit_NarA|AMR|ionophore	27.4	215	237	293	7.33e-23	93.2
C103_contig_399_127	SARG|YP_001373621	28.6	224	237	318	7.60e-23	93.6
C103_contig_399_127	SARG|gi|500194536|ref|WP_011867743.1|	27.1	229	237	306	1.24e-22	92.8
C103_contig_399_127	SARG|gi|488053456|ref|WP_002124853.1|	27.7	231	237	309	1.79e-22	92.4
C103_contig_399_127	SARG|gi|507055561|ref|WP_016126482.1|	28.0	225	237	309	2.48e-22	92.0
C103_contig_399_151	megares|MEG_6058|Drugs|MLS|23S_rRNA_methyltransferases|RLMH_1	53.5	159	160	159	3.24e-55	170
C103_contig_399_154	SARG|YP_001436495	29.8	292	292	272	1.57e-30	114
C103_contig_399_154	SARG|CAS10898	29.3	297	292	273	4.37e-30	113
C103_contig_399_154	SARG|YP_312012	29.3	297	292	273	4.37e-30	113
C103_contig_399_154	SARG|gi|641685979|emb|CDN83808.1|	29.3	297	292	274	4.46e-30	113
C103_contig_399_154	SARG|ACB16010	29.0	297	292	270	2.17e-29	111
C103_contig_399_154	SARG|YP_001590162	28.3	293	292	270	2.17e-29	111
C103_contig_399_154	SARG|gi|324115360|gb|EGC09324.1|	29.0	297	292	270	2.17e-29	111
C103_contig_399_154	SARG|A1AFX9	29.0	297	292	273	2.32e-29	111
C103_contig_399_154	SARG|YP_002042472	28.3	293	292	273	2.32e-29	111
C103_contig_399_154	SARG|YP_001573343	28.3	293	292	273	2.32e-29	111
C103_contig_399_161	SARG|gb|ABA71733.1|ARO:3002972|vanTG	34.5	365	389	712	3.05e-67	224
C103_contig_399_161	NCBI|WP_063856752.1|1|1|vanT-G|vanT-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-G|AMR|glycopeptide	32.9	368	389	711	7.37e-55	191
C103_contig_399_161	NCBI|CZR78671.1|1|1|vanT-Cd|vanT-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-Cd|AMR|glycopeptide	33.0	367	389	712	4.76e-52	183
C103_contig_399_161	SARG|gb|ABX54690.1|ARO:3002974|vanTrL	34.7	331	389	366	1.30e-51	175
C103_contig_399_161	NCBI|WP_063856756.1|1|1|vanT-C|vanT-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-C|AMR|glycopeptide	33.1	366	389	700	1.77e-48	173
C103_contig_399_161	NCBI|WP_063856755.1|1|1|vanT-C|vanT-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-C|AMR|glycopeptide	32.1	365	389	700	5.48e-46	166
C103_contig_399_161	SARG|AAY67970	30.2	364	389	698	4.96e-45	164
C103_contig_399_161	SARG|AF162694.1.gene4.p01	29.9	364	389	698	1.76e-44	162
C103_contig_399_161	SARG|gi|657686198|ref|WP_029487032.1|	29.9	364	389	698	1.76e-44	162
C103_contig_399_161	NCBI|WP_063856758.1|1|1|vanTc2|vanTc2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT|AMR|glycopeptide	30.7	365	389	706	3.90e-42	155
C103_contig_399_164	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	38.8	529	638	655	4.28e-121	373
C103_contig_399_164	SARG|gb|AKA86814|ARO:3003746|optrA	38.8	529	638	655	4.28e-121	373
C103_contig_399_164	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	38.6	529	638	655	6.60e-120	370
C103_contig_399_164	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	38.6	529	638	655	6.60e-120	370
C103_contig_399_164	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	38.6	529	638	655	1.31e-119	369
C103_contig_399_164	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	38.6	529	638	655	1.31e-119	369
C103_contig_399_164	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	38.6	529	638	655	1.31e-119	369
C103_contig_399_164	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	38.6	529	638	655	1.84e-119	369
C103_contig_399_164	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	38.6	529	638	655	1.84e-119	369
C103_contig_399_164	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	38.4	529	638	655	1.02e-118	367
C103_contig_399_300	CARD|gb|ALH22601.1|ARO:3000620|adeL	32.8	119	292	337	9.61e-12	63.5
C103_contig_399_323	megares|MEG_4323|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	25.6	544	611	655	2.21e-45	169
C103_contig_399_323	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	25.4	544	611	655	7.63e-45	168
C103_contig_399_323	megares|MEG_4321|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	25.4	544	611	655	1.04e-44	167
C103_contig_399_323	megares|MEG_4317|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	25.4	544	611	655	1.04e-44	167
C103_contig_399_323	megares|MEG_4314|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	25.4	544	611	655	1.04e-44	167
C103_contig_399_323	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	25.4	544	611	655	1.04e-44	167
C103_contig_399_323	megares|MEG_4319|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	25.4	544	611	655	1.04e-44	167
C103_contig_399_323	megares|MEG_4311|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	25.4	544	611	655	1.04e-44	167
C103_contig_399_323	megares|MEG_4305|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	25.4	544	611	655	1.04e-44	167
C103_contig_399_323	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	25.4	544	611	655	1.42e-44	167
C103_contig_399_330	SARG|gi|488374619|ref|WP_002444004.1|	27.1	417	539	452	8.40e-40	149
C103_contig_399_330	SARG|gi|505177635|ref|WP_015364737.1|	26.6	417	539	451	1.13e-39	149
C103_contig_399_330	SARG|ZP_04679156	26.6	417	539	451	7.00e-38	144
C103_contig_399_330	SARG|gi|446573707|ref|WP_000651053.1|	27.7	419	539	451	2.48e-37	142
C103_contig_399_330	SARG|gi|565830932|ref|WP_023914633.1|	27.4	419	539	451	1.20e-36	140
C103_contig_399_330	SARG|gi|537465183|ref|WP_020976941.1|	27.4	419	539	451	1.64e-36	140
C103_contig_399_330	SARG|gi|686432388|ref|WP_031921070.1|	27.4	419	539	451	2.24e-36	139
C103_contig_399_330	SARG|ZP_03986195	27.7	419	539	451	3.07e-36	139
C103_contig_399_330	SARG|gi|446573695|ref|WP_000651041.1|	27.7	419	539	451	3.07e-36	139
C103_contig_399_330	SARG|gi|1006223553|ref|WP_061745579.1|	27.3	421	539	451	3.07e-36	139
C103_contig_399_333	SARG|gb|APB03219.1|ARO:3003986|TaeA	47.2	659	622	648	4.94e-202	580
C103_contig_399_333	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	32.7	510	622	655	4.50e-72	243
C103_contig_399_333	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	32.7	510	622	655	4.50e-72	243
C103_contig_399_333	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	32.7	510	622	655	1.68e-71	242
C103_contig_399_333	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	32.7	510	622	655	1.68e-71	242
C103_contig_399_333	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	32.5	510	622	655	3.25e-71	241
C103_contig_399_333	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	32.5	510	622	655	4.52e-71	241
C103_contig_399_333	SARG|gb|AKA86814|ARO:3003746|optrA	32.5	510	622	655	4.52e-71	241
C103_contig_399_333	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	32.5	510	622	655	6.28e-71	240
C103_contig_399_333	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	32.5	510	622	655	6.28e-71	240
C103_contig_399_334	SARG|HE999704.1.gene3064.p01	27.5	200	454	241	1.45e-17	80.9
C103_contig_399_334	SARG|gi|441475675|emb|CCQ25429.1|	34.8	135	454	211	3.70e-13	67.4
C103_contig_399_346	SARG|gb|ADZ12699.1|ARO:3005091|RanA	27.3	227	264	258	3.88e-21	88.6
C103_contig_399_351	NCBI|WP_256875606.1|1|1|blaNWM-1|blaNWM|hydrolase|2|CARBAPENEM|beta-lactam|subclass_B3_metallo-beta-lactamase_NWM-1|AMR|beta-lactam	34.0	97	266	310	3.90e-06	46.2
C103_contig_399_368	SARG|gi|496018010|ref|WP_008742581.1|	30.2	248	252	623	3.56e-18	82.4
C103_contig_399_368	SARG|gi|926351744|ref|WP_053683383.1|	30.1	249	252	648	6.62e-18	81.6
C103_contig_399_368	SARG|gi|921231571|ref|WP_053176464.1|	29.8	248	252	620	8.80e-18	81.3
C103_contig_399_368	SARG|gi|917172177|ref|WP_051778889.1|	29.8	248	252	620	1.19e-17	80.9
C103_contig_399_368	SARG|gi|919568551|ref|WP_052871170.1|	29.8	248	252	620	1.19e-17	80.9
C103_contig_399_368	SARG|gi|917166849|ref|WP_051773561.1|	29.8	228	252	620	1.19e-17	80.9
C103_contig_399_368	SARG|gi|917155568|ref|WP_051762280.1|	29.8	228	252	620	1.61e-17	80.5
C103_contig_399_368	SARG|gi|917229923|ref|WP_051836635.1|	29.8	248	252	620	2.94e-17	79.7
C103_contig_399_368	SARG|gi|493394434|ref|WP_006350564.1|	29.4	231	252	602	3.93e-17	79.3
C103_contig_399_368	SARG|gi|926294973|ref|WP_053631154.1|	28.6	248	252	620	1.80e-16	77.4
C103_contig_117_6	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	55.3	244	273	255	4.75e-96	281
C103_contig_117_6	SARG|gi|495736522|ref|WP_008461101.1|	38.4	203	273	648	1.05e-42	153
C103_contig_117_6	SARG|gi|746253210|ref|WP_039301529.1|	38.4	203	273	648	1.45e-42	152
C103_contig_117_6	SARG|gi|1001720867|ref|WP_061274204.1|	38.4	203	273	648	1.45e-42	152
C103_contig_117_6	SARG|gi|803568669|ref|WP_046077412.1|	39.2	204	273	648	3.79e-42	151
C103_contig_117_6	SARG|gi|446110352|ref|WP_000188207.1|	39.2	204	273	648	3.79e-42	151
C103_contig_117_6	SARG|YP_002382193	39.2	204	273	648	3.79e-42	151
C103_contig_117_6	SARG|gi|803575554|ref|WP_046081557.1|	39.2	204	273	648	3.79e-42	151
C103_contig_117_6	SARG|gi|446110351|ref|WP_000188206.1|	39.2	204	273	648	3.79e-42	151
C103_contig_117_6	SARG|gi|555268037|ref|WP_023249477.1|	39.4	208	273	648	7.19e-42	150
C103_contig_117_9	NCBI|XSG12259.1|1|1|drcR|drcR||1|||daptomycin_efflux_response_regulator_transcription_factor_DrcR|AMR|peptide	34.1	220	220	223	3.39e-40	136
C103_contig_117_9	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	28.0	207	220	229	4.02e-29	107
C103_contig_117_9	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	26.1	207	220	230	1.72e-27	103
C103_contig_117_9	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	24.3	210	220	231	1.88e-26	100
C103_contig_117_9	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	23.6	208	220	231	3.69e-26	100
C103_contig_117_9	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	28.6	231	220	239	3.30e-25	97.8
C103_contig_117_9	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	23.1	208	220	231	1.07e-24	96.3
C103_contig_117_9	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	23.1	208	220	231	1.50e-24	95.9
C103_contig_117_9	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	25.1	211	220	233	4.50e-23	92.0
C103_contig_117_9	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	23.3	227	220	252	1.71e-15	72.0
C103_contig_117_10	NCBI|XSG12258.1|1|1|drcS|drcS||1|||daptomycin_efflux_sensor_histidine_kinase_DrcS|AMR|peptide	37.1	278	338	341	5.16e-59	192
C103_contig_117_22	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	46.5	256	261	255	2.20e-81	244
C103_contig_117_22	SARG|gi|823326845|ref|WP_047080664.1|	38.0	234	261	648	1.26e-48	169
C103_contig_117_22	SARG|gi|976146774|ref|WP_059305359.1|	38.0	234	261	648	1.26e-48	169
C103_contig_117_22	SARG|gi|1022664304|ref|WP_063420886.1|	38.0	234	261	648	1.26e-48	169
C103_contig_117_22	SARG|gi|505807117|ref|WP_015704872.1|	38.0	234	261	648	1.26e-48	169
C103_contig_117_22	SARG|gi|695797094|ref|WP_032711285.1|	38.0	234	261	648	1.26e-48	169
C103_contig_117_22	SARG|gi|823299155|ref|WP_047054544.1|	38.0	234	261	648	1.26e-48	169
C103_contig_117_22	SARG|gi|823302270|ref|WP_047057473.1|	38.0	234	261	648	1.74e-48	168
C103_contig_117_22	SARG|gi|639209604|ref|WP_024547784.1|	37.4	219	261	648	1.74e-48	168
C103_contig_117_22	SARG|gi|823309640|ref|WP_047064288.1|	38.0	234	261	648	1.74e-48	168
C103_contig_117_23	NCBI|XSG12257.1|1|1|drcB|drcB||1|||daptomycin_efflux_ABC_transporter_permease_DrcB|AMR|peptide	21.8	652	717	641	5.29e-13	71.2
C103_contig_117_24	NCBI|XSG12259.1|1|1|drcR|drcR||1|||daptomycin_efflux_response_regulator_transcription_factor_DrcR|AMR|peptide	33.3	219	228	223	8.68e-40	135
C103_contig_117_24	NCBI|WP_011029105.1|1|1|vanR-Sc|vanR-Sc|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-Sc|AMR|glycopeptide	33.2	220	228	231	4.89e-30	110
C103_contig_117_24	NCBI|WP_063856729.1|1|1|vanR-O|vanR-O|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-O|AMR|glycopeptide	31.8	220	228	233	6.68e-26	99.8
C103_contig_117_29	SARG|DQ212986.1.gene3.p01	42.9	63	67	75	3.50e-16	64.7
C103_contig_117_41	megares|MEG_5148|Drugs|beta-lactam|Class_D_betalactamases|OXA_1	41.0	61	231	346	1.22e-06	47.4
C103_contig_117_60	CARD|gb|BAB36671.1|ARO:3000832|evgA	24.1	133	260	204	4.77e-07	48.1
C103_contig_117_98	CARD|gb|BAB36671.1|ARO:3000832|evgA	25.7	101	357	204	1.50e-09	56.2
C103_contig_117_98	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	26.9	104	357	228	2.37e-07	50.1
C103_contig_117_106	SARG|HE999704.1.gene3064.p01	33.3	201	457	241	1.84e-28	111
C103_contig_117_106	SARG|gi|441475675|emb|CCQ25429.1|	33.3	153	457	211	2.04e-19	85.5
C103_contig_117_110	SARG|gb|SOX29786.1|ARO:3004730|tva(A)	28.3	198	244	505	3.09e-11	61.6
C103_contig_117_110	ResF|poxtA-Ef_1_WP094899500.1_1	24.2	223	244	538	2.72e-09	55.8
C103_contig_117_110	megares|MEG_8639|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|POXT_1	24.2	223	244	543	2.73e-09	55.8
C103_contig_117_110	NCBI|WP_094899500.1|1|1|poxtA-Ef|poxtA-Ef|target_protection|2|CHLORAMPHENICOL/FLORFENICOL/LINEZOLID|OXAZOLIDINONE/PHENICOL|ABC-F_type_ribosomal_protection_protein_PoxtA-Ef|AMR|multidrug	24.2	223	244	543	2.73e-09	55.8
C103_contig_117_110	SARG|gi|951389844|ref|WP_057765492.1|	27.2	191	244	492	2.07e-08	53.1
C103_contig_117_110	SARG|gi|727118387|ref|WP_033626720.1|	28.1	199	244	498	3.75e-08	52.4
C103_contig_117_110	SARG|gi|488349878|ref|WP_002419263.1|	29.0	183	244	498	5.04e-08	52.0
C103_contig_117_110	SARG|gi|498528849|ref|WP_010828356.1|	27.6	199	244	498	5.04e-08	52.0
C103_contig_117_110	SARG|gi|488310376|ref|WP_002379761.1|	28.1	199	244	498	5.04e-08	52.0
C103_contig_117_110	SARG|gi|514883218|ref|WP_016615053.1|	28.1	199	244	498	6.76e-08	51.6
C103_contig_117_119	NCBI|WP_109545033.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	30.1	256	418	355	5.62e-25	103
C103_contig_117_119	megares|MEG_7602|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	30.1	256	418	355	5.62e-25	103
C103_contig_117_119	SARG|ACM47285	30.1	256	418	363	6.27e-25	103
C103_contig_117_119	megares|MEG_7603|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	27.9	301	418	355	2.67e-24	102
C103_contig_117_119	SARG|BAE96115	27.9	301	418	355	2.67e-24	102
C103_contig_117_119	NCBI|WP_063856862.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	29.7	256	418	356	2.71e-24	102
C103_contig_117_119	NCBI|WP_049898469.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	29.3	256	418	356	9.39e-24	100
C103_contig_117_119	NCBI|WP_063856854.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	28.9	256	418	356	1.52e-22	97.1
C103_contig_117_120	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	45.0	1048	1081	1033	0.0	928
C103_contig_117_120	SARG|gb|AEY83581|ARO:3000510|mupB	45.0	1048	1081	1033	0.0	928
C103_contig_117_120	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	43.3	1044	1081	1024	0.0	918
C103_contig_117_120	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	43.3	1044	1081	1024	0.0	918
C103_contig_117_120	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	43.0	1044	1081	1024	2.49e-319	910
C103_contig_117_120	SARG|gb|CAA53189|ARO:3000521|mupA	43.0	1044	1081	1024	2.49e-319	910
C103_contig_117_120	megares|MEG_3295|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|ILES_1	36.6	1068	1081	1107	1.65e-216	649
C103_contig_117_120	SARG|gb|ADP36409.1|ARO:3003730|Bifidobacteria	36.6	1068	1081	1107	1.65e-216	649
C103_contig_117_237	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	35.6	216	340	255	6.51e-42	145
C103_contig_117_237	SARG|gb|AHB37625.1|ARO:3004715|vga(E)	28.1	196	340	524	5.67e-10	59.3
C103_contig_117_267	CARD|gb|BAD59497.1|ARO:3000501|rpoB2	53.2	1237	1285	1162	0.0	1209
C103_contig_117_267	CARD|gb|WP_041777404.1|ARO:3004480|Bado_rpoB_RIF	51.5	1240	1285	1186	0.0	1155
C103_contig_117_267	megares|MEG_8674|Drugs|Rifampin|Rifampin-resistant_beta-subunit_of_RNA_polymerase_RpoB|RPOB_1	51.5	1240	1285	1186	0.0	1155
C103_contig_117_276	SARG|L42544.gene.p01	28.3	668	708	651	1.35e-75	255
C103_contig_117_276	SARG|NP_348076	28.7	679	708	652	1.37e-75	255
C103_contig_117_276	SARG|AAV80410	28.3	668	708	651	2.60e-75	254
C103_contig_117_276	SARG|YP_002850805	27.8	691	708	652	2.61e-72	246
C103_contig_117_276	SARG|ZP_02952732	28.1	691	708	652	3.57e-71	243
C103_contig_117_276	SARG|ZP_02632674	28.1	691	708	660	4.18e-71	243
C103_contig_117_276	SARG|L20800.gene.p01	28.1	691	708	652	1.32e-70	241
C103_contig_117_276	megares|MEG_7175|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	27.6	682	708	639	3.16e-64	224
C103_contig_117_276	SARG|AJ514254.gene.p01	26.7	696	708	640	6.13e-64	223
C103_contig_117_276	SARG|gi|544707441|ref|WP_021137831.1|	27.2	685	708	639	5.47e-62	218
C103_contig_117_277	SARG|ACF08831	37.3	150	398	639	1.08e-17	84.0
C103_contig_117_277	NCBI|WP_050824634.1|1|1|tet(O)|tet(O)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(O)|AMR|tetracycline	35.9	153	398	639	1.10e-15	77.8
C103_contig_117_280	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	37.0	230	230	231	7.43e-47	154
C103_contig_117_280	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	36.5	230	230	231	2.09e-46	152
C103_contig_117_280	CARD|gb|AAG05188.1|ARO:3005068|ParR	36.7	221	230	235	6.61e-46	151
C103_contig_117_280	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	35.2	230	230	231	9.36e-45	148
C103_contig_117_280	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	34.3	233	230	239	2.05e-42	142
C103_contig_117_280	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	35.7	224	230	232	1.84e-38	132
C103_contig_117_280	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	35.7	224	230	228	7.22e-37	128
C103_contig_117_280	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	30.5	233	230	252	3.95e-31	114
C103_contig_117_281	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	25.2	214	387	359	2.45e-16	78.6
C103_contig_117_281	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	24.7	198	387	381	3.02e-15	75.5
C103_contig_117_281	megares|MEG_7504|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	24.7	198	387	381	3.02e-15	75.5
C103_contig_117_281	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	24.8	202	387	367	1.21e-14	73.6
C103_contig_117_281	NCBI|WP_021418927.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	24.8	202	387	368	1.22e-14	73.6
C103_contig_117_281	NCBI|AXB64455.1|1|1|vanS-Cd|vanS-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|VanG-Cd-type_glycopeptide_resistance_histidine_kinase_VanS|AMR|glycopeptide	23.7	215	387	380	1.01e-13	70.9
C103_contig_117_281	megares|MEG_7498|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	23.7	215	387	380	1.01e-13	70.9
C103_contig_117_281	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	22.4	205	387	381	1.02e-13	70.9
C103_contig_117_281	megares|MEG_7505|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	22.3	206	387	381	1.02e-13	70.9
C103_contig_117_281	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	22.4	205	387	381	1.02e-13	70.9
C103_contig_117_294	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	29.1	234	333	255	6.70e-22	92.0
C103_contig_117_294	SARG|gi|696411918|ref|WP_032982657.1|	32.8	235	333	647	8.78e-22	95.1
C103_contig_117_294	SARG|gi|835233765|ref|WP_047410073.1|	30.7	274	333	648	1.60e-21	94.4
C103_contig_117_294	SARG|gi|923061916|ref|WP_053445667.1|	31.0	242	333	648	2.90e-21	93.6
C103_contig_117_294	SARG|gi|696402390|ref|WP_032974230.1|	32.3	235	333	647	3.90e-21	93.2
C103_contig_117_294	SARG|gi|495067432|ref|WP_007792257.1|	32.3	235	333	647	3.90e-21	93.2
C103_contig_117_294	SARG|gi|742378414|ref|WP_038857601.1|	30.3	264	333	647	3.90e-21	93.2
C103_contig_117_294	SARG|gi|696423952|ref|WP_032993748.1|	32.3	235	333	647	3.90e-21	93.2
C103_contig_117_294	SARG|YP_001571041	31.6	247	333	648	3.90e-21	93.2
C103_contig_117_294	SARG|gi|960873409|ref|WP_058345546.1|	31.6	247	333	648	3.90e-21	93.2
C103_contig_117_295	SARG|gi|974633183|ref|WP_059219858.1|	35.6	208	326	648	5.25e-23	98.6
C103_contig_117_295	SARG|gi|974684692|ref|WP_059267998.1|	35.6	208	326	648	5.25e-23	98.6
C103_contig_117_295	SARG|gi|974672242|ref|WP_059256507.1|	35.6	208	326	648	9.56e-23	97.8
C103_contig_117_295	SARG|gi|974641719|ref|WP_059227752.1|	35.6	208	326	648	9.56e-23	97.8
C103_contig_117_295	SARG|gi|643601187|ref|WP_025237288.1|	35.6	208	326	648	9.56e-23	97.8
C103_contig_117_295	SARG|gi|974628291|ref|WP_059215695.1|	35.6	208	326	648	9.56e-23	97.8
C103_contig_117_295	SARG|gi|446110298|ref|WP_000188153.1|	35.6	208	326	648	9.56e-23	97.8
C103_contig_117_295	SARG|gi|446110299|ref|WP_000188154.1|	35.6	208	326	648	9.56e-23	97.8
C103_contig_117_295	SARG|ZP_02903696	35.6	208	326	648	9.56e-23	97.8
C103_contig_117_295	SARG|gi|974688082|ref|WP_059271287.1|	35.6	208	326	648	9.56e-23	97.8
C103_contig_117_309	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	30.0	270	964	365	1.84e-26	111
C103_contig_117_309	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	29.8	292	964	370	2.00e-26	111
C103_contig_117_309	megares|MEG_7505|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	31.0	242	964	381	1.52e-24	105
C103_contig_117_309	NCBI|WP_063856730.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	31.0	242	964	381	1.52e-24	105
C103_contig_117_309	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	32.3	226	964	381	3.69e-24	104
C103_contig_117_309	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	32.3	226	964	381	3.69e-24	104
C103_contig_117_309	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	30.6	242	964	381	8.97e-24	103
C103_contig_117_309	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	30.6	242	964	381	8.97e-24	103
C103_contig_117_309	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	29.0	241	964	367	4.35e-23	101
C103_contig_117_309	NCBI|WP_021418927.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	29.0	241	964	368	4.41e-23	101
C103_contig_117_310	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	44.8	230	232	232	5.94e-76	228
C103_contig_117_310	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	44.8	230	232	232	5.94e-76	228
C103_contig_117_310	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	44.4	225	232	231	3.79e-74	223
C103_contig_117_310	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	43.3	231	232	235	1.41e-72	219
C103_contig_117_310	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	46.5	228	232	231	1.00e-71	217
C103_contig_117_310	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	46.5	228	232	231	1.00e-71	217
C103_contig_117_310	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	42.0	224	232	232	5.93e-71	215
C103_contig_117_310	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	42.2	230	232	229	1.08e-70	214
C103_contig_117_310	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	44.7	228	232	231	2.32e-70	214
C103_contig_117_310	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	43.9	228	232	231	3.28e-70	213
C103_contig_117_316	SARG|gb|APB03216.1|ARO:3003982|LlmA	62.4	287	287	287	5.99e-139	392
C103_contig_117_319	SARG|gi|1028100561|ref|WP_063856696.1|	31.7	350	345	349	9.10e-43	150
C103_contig_117_319	SARG|gi|752682279|ref|WP_041330231.1|	31.6	351	345	349	2.49e-42	149
C103_contig_117_319	SARG|DQ212986.1.gene8.p01	31.5	349	345	349	9.54e-42	147
C103_contig_117_319	SARG|gi|405945042|pdb|4FU0|A	31.5	349	345	357	1.13e-41	147
C103_contig_117_319	SARG|gi|765411304|ref|WP_044689514.1|	31.5	349	345	349	1.86e-41	147
C103_contig_117_319	SARG|AAF71281	31.2	349	345	349	5.09e-41	145
C103_contig_117_320	megares|MEG_7572|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	38.6	453	456	481	1.02e-92	288
C103_contig_117_320	megares|MEG_7571|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	38.4	453	456	451	7.53e-91	282
C103_contig_117_320	megares|MEG_7563|Drugs|Glycopeptide|VanB-type_resistance_protein|VANXB_2	37.7	453	456	451	1.50e-90	281
C103_contig_117_322	SARG|gi|746609237|ref|WP_039635344.1|	30.7	303	319	322	7.21e-35	128
C103_contig_117_322	SARG|DQ018711.1.gene4.p01	32.4	278	319	322	1.40e-34	127
C103_contig_117_322	SARG|gi|738848198|ref|WP_036737307.1|	32.5	286	319	323	7.57e-34	125
C103_contig_117_322	SARG|gi|737310392|ref|WP_035293250.1|	31.7	278	319	323	2.09e-32	121
C103_contig_117_322	SARG|AF155139.2.gene6.p01	31.0	277	319	322	2.89e-31	118
C103_contig_117_322	SARG|FJ349556.1.gene5.p01	30.7	300	319	326	6.03e-31	117
C103_contig_117_322	NCBI|WP_063856705.1|1|1|vanH-D|vanH-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-D|AMR|glycopeptide	29.4	289	319	323	1.54e-29	114
C103_contig_117_322	SARG|gi|552942232|ref|WP_023043160.1|	30.1	289	319	323	1.08e-27	108
C103_contig_117_322	SARG|AY082011.1.gene6.p01	29.8	289	319	323	7.67e-27	106
C103_contig_117_322	NCBI|WP_063856700.1|1|1|vanH-Ao2|vanH-Ao2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ao2|AMR|glycopeptide	28.1	256	319	343	5.30e-26	104
C103_contig_117_343	SARG|L42544.gene.p01	29.2	356	612	651	3.65e-30	124
C103_contig_117_343	SARG|AAV80410	29.2	356	612	651	3.65e-30	124
C103_contig_117_343	SARG|AJ514254.gene.p01	34.3	230	612	640	1.12e-28	120
C103_contig_117_343	SARG|Q02652	44.8	145	612	639	6.13e-26	111
C103_contig_117_343	SARG|ABB70054	44.5	128	612	639	3.19e-23	103
C103_contig_117_343	SARG|ABI81214	44.5	128	612	639	3.19e-23	103
C103_contig_117_343	SARG|BAB71968	44.5	128	612	639	3.19e-23	103
C103_contig_117_343	SARG|YP_002738300	44.5	128	612	639	3.19e-23	103
C103_contig_117_343	SARG|gi|658130997|emb|CDO19407.1|	25.5	443	612	644	3.23e-23	103
C103_contig_117_343	SARG|ABG21123	40.4	146	612	639	4.23e-23	102
C103_contig_117_423	NCBI|XSG12259.1|1|1|drcR|drcR||1|||daptomycin_efflux_response_regulator_transcription_factor_DrcR|AMR|peptide	48.9	221	223	223	3.67e-75	225
C103_contig_117_423	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	32.1	218	223	219	1.82e-36	126
C103_contig_117_423	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	32.1	218	223	219	2.57e-36	126
C103_contig_117_423	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	32.1	218	223	220	2.63e-36	126
C103_contig_117_423	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	32.1	218	223	220	3.71e-36	125
C103_contig_117_423	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	33.0	230	223	231	2.74e-35	124
C103_contig_117_423	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	31.9	226	223	231	4.24e-34	120
C103_contig_117_423	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	31.0	226	223	231	1.18e-33	119
C103_contig_117_423	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	30.7	228	223	230	3.22e-33	118
C103_contig_117_423	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	31.0	229	223	233	3.46e-33	118
C103_contig_117_424	NCBI|XSG12258.1|1|1|drcS|drcS||1|||daptomycin_efflux_sensor_histidine_kinase_DrcS|AMR|peptide	38.1	252	328	341	1.41e-55	183
C103_contig_117_458	SARG|gi|766974935|ref|WP_044866868.1|	38.3	230	249	648	3.24e-41	148
C103_contig_117_458	SARG|gi|446110269|ref|WP_000188124.1|	38.3	230	249	648	6.15e-41	147
C103_contig_117_458	SARG|YP_002328441	38.3	230	249	648	6.15e-41	147
C103_contig_117_458	SARG|gi|446110301|ref|WP_000188156.1|	38.3	230	249	648	6.15e-41	147
C103_contig_117_458	SARG|gi|391288090|gb|EIQ46599.1|	38.3	230	249	645	1.14e-40	146
C103_contig_117_458	SARG|gi|693106883|ref|WP_032260279.1|	38.3	230	249	648	1.17e-40	146
C103_contig_117_458	SARG|gi|446110295|ref|WP_000188150.1|	37.8	230	249	648	1.17e-40	146
C103_contig_117_458	SARG|gi|545167026|ref|WP_021521592.1|	37.8	230	249	648	1.60e-40	146
C103_contig_117_458	SARG|gi|754724054|ref|WP_042095806.1|	37.8	230	249	648	1.60e-40	146
C103_contig_117_458	SARG|gi|971845730|ref|WP_058914924.1|	38.3	230	249	648	1.60e-40	146
C103_contig_117_466	SARG|gb|AAK76137.1|ARO:3000024|patA	30.9	236	265	564	1.22e-16	78.2
C103_contig_117_467	SARG|gb|CDO61516.1|ARO:3003949|efrB	30.5	190	254	362	9.06e-18	80.5
C103_contig_117_467	SARG|gi|498517610|ref|WP_010817605.1|	27.6	221	254	498	4.07e-09	55.5
C103_contig_117_467	SARG|gi|498399452|ref|WP_010712758.1|	27.6	221	254	498	4.07e-09	55.5
C103_contig_117_467	SARG|gi|514908720|ref|WP_016633351.1|	27.1	221	254	498	4.07e-09	55.5
C103_contig_117_467	SARG|gi|498524203|ref|WP_010823919.1|	27.1	221	254	498	5.47e-09	55.1
C103_contig_117_467	SARG|gi|488311349|ref|WP_002380734.1|	27.1	221	254	498	7.34e-09	54.7
C103_contig_117_467	SARG|gi|498393490|ref|WP_010707193.1|	27.1	221	254	498	7.34e-09	54.7
C103_contig_117_467	SARG|gi|727017227|ref|WP_033592736.1|	27.1	221	254	498	7.34e-09	54.7
C103_contig_117_467	SARG|gi|498399943|ref|WP_010713140.1|	27.1	221	254	498	7.34e-09	54.7
C103_contig_117_467	SARG|gi|895828321|ref|WP_048949453.1|	27.1	221	254	498	7.34e-09	54.7
C103_contig_117_471	SARG|gi|446048013|ref|WP_000125868.1|	30.8	237	313	648	4.97e-24	101
C103_contig_117_471	SARG|gi|921979807|ref|WP_053271336.1|	33.0	209	313	648	9.08e-24	100
C103_contig_117_471	SARG|gb|AYV52072.1|ARO:3002882|lmrD	26.1	230	313	664	2.69e-12	66.2
C103_contig_117_471	SARG|gb|AAK76136.1|ARO:3000025|patB	24.0	229	313	588	1.99e-08	54.3
C103_contig_117_471	SARG|gi|764446018|ref|WP_044369325.1|	24.2	207	313	605	2.01e-08	54.3
C103_contig_117_471	SARG|gi|943938624|ref|WP_055567802.1|	24.2	207	313	602	3.57e-08	53.5
C103_contig_117_471	SARG|gi|1045390184|ref|WP_065479071.1|	23.7	207	313	605	3.57e-08	53.5
C103_contig_117_471	SARG|gi|695887424|ref|WP_032788534.1|	23.7	207	313	605	6.33e-08	52.8
C103_contig_117_471	SARG|gi|664180077|ref|WP_030714054.1|	23.7	207	313	605	6.33e-08	52.8
C103_contig_117_471	SARG|gi|664170108|ref|WP_030704355.1|	23.7	207	313	603	8.42e-08	52.4
C103_contig_117_480	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	48.2	251	256	255	1.71e-84	251
C103_contig_117_480	SARG|gi|823326845|ref|WP_047080664.1|	39.8	221	256	648	1.54e-54	184
C103_contig_117_480	SARG|gi|823302270|ref|WP_047057473.1|	39.8	221	256	648	2.98e-54	184
C103_contig_117_480	SARG|gi|976146774|ref|WP_059305359.1|	39.8	221	256	648	2.98e-54	184
C103_contig_117_480	SARG|gi|1022664304|ref|WP_063420886.1|	39.8	221	256	648	2.98e-54	184
C103_contig_117_480	SARG|gi|823309640|ref|WP_047064288.1|	39.8	221	256	648	2.98e-54	184
C103_contig_117_480	SARG|gi|505807117|ref|WP_015704872.1|	39.8	221	256	648	2.98e-54	184
C103_contig_117_480	SARG|gi|518923394|ref|WP_020079269.1|	39.8	221	256	648	2.98e-54	184
C103_contig_117_480	SARG|gi|695797094|ref|WP_032711285.1|	39.8	221	256	648	2.98e-54	184
C103_contig_117_480	SARG|gi|823299155|ref|WP_047054544.1|	39.8	221	256	648	2.98e-54	184
C103_contig_117_487	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	39.4	251	249	255	2.71e-49	161
C103_contig_117_487	SARG|gi|516510995|ref|WP_017899433.1|	40.9	220	249	646	2.59e-43	154
C103_contig_117_487	SARG|gi|1031822889|ref|WP_064150402.1|	40.5	220	249	646	1.29e-42	152
C103_contig_117_487	SARG|gi|490306253|ref|WP_004201358.1|	40.5	220	249	646	1.29e-42	152
C103_contig_117_487	SARG|gi|950164608|ref|WP_057214157.1|	40.5	220	249	646	1.29e-42	152
C103_contig_117_487	SARG|gi|694113305|ref|WP_032455256.1|	40.5	220	249	646	1.29e-42	152
C103_contig_117_487	SARG|gi|764951644|ref|WP_044521907.1|	40.5	220	249	646	1.29e-42	152
C103_contig_117_487	SARG|gi|896073592|ref|WP_049116987.1|	40.5	220	249	646	1.29e-42	152
C103_contig_117_487	SARG|gi|927316447|ref|WP_053810605.1|	40.5	220	249	646	1.29e-42	152
C103_contig_117_487	SARG|gi|556468297|ref|WP_023320056.1|	40.5	220	249	646	1.29e-42	152
C103_contig_117_493	megares|MEG_7572|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	25.7	447	486	481	2.73e-19	89.4
C103_contig_117_493	megares|MEG_7571|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	24.3	456	486	451	5.72e-18	85.1
C103_contig_117_496	SARG|B1LLK9	33.1	317	319	660	1.53e-46	165
C103_contig_117_496	SARG|gi|550713000|ref|WP_022645909.1|	32.8	317	319	660	7.66e-46	163
C103_contig_117_496	SARG|gi|507079934|ref|WP_016150692.1|	32.5	317	319	660	1.46e-45	162
C103_contig_117_496	SARG|gi|851917461|ref|WP_048217311.1|	32.5	317	319	660	2.01e-45	162
C103_contig_117_496	SARG|gi|696375142|ref|WP_032949690.1|	32.5	317	319	660	2.01e-45	162
C103_contig_117_496	SARG|gi|851981245|ref|WP_048240645.1|	32.5	317	319	660	2.01e-45	162
C103_contig_117_496	SARG|gi|765458296|ref|WP_044714032.1|	32.2	317	319	660	3.82e-45	161
C103_contig_117_496	SARG|gi|446783041|ref|WP_000860297.1|	32.5	317	319	660	3.82e-45	161
C103_contig_117_496	SARG|gi|486422571|ref|WP_001613499.1|	32.5	317	319	660	5.27e-45	161
C103_contig_117_496	SARG|gi|489117806|ref|WP_003027650.1|	32.2	317	319	660	7.26e-45	160
C103_contig_117_499	SARG|gb|BAD63613.1|ARO:3002816|clbC	35.1	342	347	350	6.67e-58	190
C103_contig_117_499	NCBI|WP_032491462.1|1|1|cfr|cfr|target_modification|2|CHLORAMPHENICOL/CLINDAMYCIN/FLORFENICOL/LINEZOLID/STREPTOGRAMIN_B/TIAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/OXAZOLIDINONE/PHENICOL/PLEUROMUTILIN/STREPTOGRAMIN|23S_rRNA_(adenine(2503)-C(8))-methyltransferase_Cfr|AMR|multidrug	35.1	342	347	349	9.98e-57	187
C103_contig_117_499	SARG|AJ249217.gene.p01	35.1	342	347	349	2.78e-56	186
C103_contig_117_501	CARD|gb|WKR28567.1|ARO:3007678|IreK	33.1	688	748	718	8.64e-78	263
C103_contig_117_511	megares|MEG_5400|Drugs|beta-lactam|Penicillin_binding_protein|PBP2_1	24.2	608	558	633	1.93e-32	130
C103_contig_117_525	SARG|gi|445996719|ref|WP_000074574.1|	30.4	230	253	309	1.85e-28	108
C103_contig_117_525	SARG|gi|445996710|ref|WP_000074565.1|	30.0	240	253	309	1.85e-28	108
C103_contig_117_525	SARG|gi|500465078|gb|EOP76697.1|	30.3	234	253	306	2.45e-28	108
C103_contig_117_525	SARG|gi|895736250|emb|COF64653.1|	29.6	240	253	309	1.36e-27	106
C103_contig_117_525	SARG|gi|446110087|ref|WP_000187942.1|	29.6	240	253	309	1.36e-27	106
C103_contig_117_525	SARG|gi|507035724|ref|WP_016107411.1|	30.0	233	253	309	1.89e-27	106
C103_contig_117_525	SARG|gi|445996698|ref|WP_000074553.1|	30.0	233	253	309	1.89e-27	106
C103_contig_117_525	SARG|gi|445996714|ref|WP_000074569.1|	30.0	230	253	309	1.89e-27	106
C103_contig_117_525	SARG|gi|445996697|ref|WP_000074552.1|	30.0	233	253	309	2.63e-27	105
C103_contig_117_525	SARG|gi|445996696|ref|WP_000074551.1|	30.0	233	253	309	2.63e-27	105
C103_contig_117_526	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	32.1	215	237	343	5.46e-23	94.4
C103_contig_117_526	SARG|YP_001176128	27.0	241	237	646	2.58e-18	82.4
C103_contig_117_526	SARG|gi|974588181|ref|WP_059178476.1|	27.1	221	237	646	4.73e-18	81.6
C103_contig_117_526	SARG|gi|749017716|ref|WP_040076354.1|	27.6	221	237	646	4.73e-18	81.6
C103_contig_117_526	SARG|gi|763407609|ref|WP_044264203.1|	25.9	239	237	648	4.74e-18	81.6
C103_contig_117_526	SARG|gi|976150171|ref|WP_059308384.1|	27.2	228	237	646	6.41e-18	81.3
C103_contig_117_526	SARG|gi|968563772|ref|WP_058587854.1|	25.9	239	237	648	8.69e-18	80.9
C103_contig_117_526	SARG|gi|757782629|ref|WP_043001213.1|	25.9	239	237	648	8.69e-18	80.9
C103_contig_117_526	SARG|gi|754964360|ref|WP_042320280.1|	25.2	238	237	648	1.18e-17	80.5
C103_contig_117_526	SARG|gi|992390012|ref|WP_061077002.1|	25.9	239	237	648	1.18e-17	80.5
C103_contig_117_550	CARD|gb|AAC75429.1|ARO:3000833|evgS	29.2	394	1073	1197	6.86e-32	134
C103_contig_117_550	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	26.0	265	1073	359	2.47e-18	87.0
C103_contig_117_550	CARD|gb|AEX49906.1|ARO:3003583|basS	27.7	231	1073	477	7.76e-15	77.4
C103_contig_117_553	SARG|gb|AAC75089.1|ARO:3003577|ugd	58.5	407	412	388	1.30e-163	464
C103_contig_117_597	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	24.8	109	541	231	7.54e-08	52.4
C103_contig_117_597	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	25.7	109	541	232	1.95e-06	48.1
C103_contig_117_602	SARG|P42332	27.9	215	504	306	7.70e-21	92.0
C103_contig_117_602	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	27.9	215	504	306	7.70e-21	92.0
C103_contig_117_602	SARG|gi|510143239|gb|AGN36970.1|	27.9	215	504	313	8.54e-21	92.0
C103_contig_117_602	SARG|ABB80128	27.9	215	504	306	1.41e-20	91.3
C103_contig_117_602	SARG|AAD21213	27.9	215	504	306	2.58e-20	90.5
C103_contig_117_602	SARG|gb|AAK76137.1|ARO:3000024|patA	27.4	223	504	564	2.30e-12	68.2
C103_contig_117_602	SARG|gb|WP_104671188.1|ARO:3003948|efrA	24.0	217	504	575	1.91e-09	58.9
C103_contig_117_602	SARG|gi|953808775|ref|WP_058042812.1|	33.3	78	504	608	2.70e-06	48.9
C103_contig_117_602	SARG|gi|748767925|ref|WP_040019608.1|	23.5	217	504	623	2.73e-06	48.9
C103_contig_117_602	SARG|AF170880.4.gene1.p01	24.2	161	504	615	3.58e-06	48.5
C103_contig_117_609	SARG|gi|921979807|ref|WP_053271336.1|	27.2	228	504	648	1.43e-17	84.7
C103_contig_117_609	SARG|gi|446048013|ref|WP_000125868.1|	26.6	233	504	648	1.82e-16	81.3
C103_contig_117_609	SARG|gb|AAK76137.1|ARO:3000024|patA	25.4	279	504	564	7.05e-12	66.6
C103_contig_117_609	SARG|gi|694064328|ref|WP_032410816.1|	25.0	208	504	646	2.37e-11	65.1
C103_contig_117_609	SARG|gb|APB03219.1|ARO:3003986|TaeA	19.9	493	504	648	2.38e-11	65.1
C103_contig_117_609	SARG|gi|445996710|ref|WP_000074565.1|	27.4	208	504	309	6.70e-11	62.4
C103_contig_117_609	SARG|gb|CDO61516.1|ARO:3003949|efrB	25.1	187	504	362	1.64e-10	61.6
C103_contig_117_609	SARG|gi|488120365|ref|WP_002191762.1|	25.2	222	504	309	5.11e-10	59.7
C103_contig_117_609	SARG|gi|507055561|ref|WP_016126482.1|	24.5	208	504	309	5.11e-10	59.7
C103_contig_117_609	SARG|gi|814314593|emb|CKF49145.1|	27.1	207	504	309	5.11e-10	59.7
C103_contig_117_614	NCBI|AAD44693.1|1|1|mtrA_Ngon|mtrA_Ngon||1|EFFLUX|EFFLUX|efflux_transporter_MtrCDE_transcriptional_activator_MtrA|AMR|efflux	25.6	129	311	301	8.24e-10	57.8
C103_contig_117_623	SARG|gb|AYV52072.1|ARO:3002882|lmrD	29.9	224	511	664	8.68e-18	85.5
C103_contig_117_623	SARG|gb|AAC75271.1|ARO:3003952|yojI	28.0	218	511	547	4.50e-14	73.6
C103_contig_117_623	SARG|gb|AAR96051.1|ARO:3002894|otrC	22.5	351	511	351	1.59e-10	61.6
C103_contig_117_623	megares|MEG_4383|Drugs|Tetracycline|Tetracycline_resistance_ABC_efflux_pumps|OTRC_1	22.5	351	511	351	1.59e-10	61.6
C103_contig_117_623	NCBI|WP_289811734.1|1|1|tetA(60)|tetA(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_A|AMR|tetracycline	27.7	202	511	579	2.22e-07	52.4
C103_contig_117_623	SARG|gb|ANZ79240.1|ARO:3004035|tetA(60)	27.7	202	511	579	2.22e-07	52.4
C103_contig_117_632	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	25.5	220	399	255	5.26e-16	76.3
C103_contig_117_632	SARG|gi|1016275448|gb|AMX06027.1|	27.0	244	399	646	1.11e-15	77.8
C103_contig_117_632	SARG|gi|1045891604|ref|WP_065554100.1|	28.1	270	399	648	1.49e-15	77.4
C103_contig_117_632	SARG|gi|507082903|ref|WP_016153652.1|	28.1	270	399	648	1.49e-15	77.4
C103_contig_117_632	SARG|gi|507086196|ref|WP_016156937.1|	28.1	270	399	648	1.98e-15	77.0
C103_contig_117_632	SARG|YP_001571041	25.0	256	399	648	1.98e-15	77.0
C103_contig_117_632	SARG|gi|960873409|ref|WP_058345546.1|	25.0	256	399	648	1.98e-15	77.0
C103_contig_117_632	SARG|gi|835233765|ref|WP_047410073.1|	28.5	270	399	648	2.64e-15	76.6
C103_contig_117_632	SARG|gi|1033064422|ref|WP_064375412.1|	26.1	249	399	648	2.64e-15	76.6
C103_contig_117_632	SARG|gi|922960663|ref|WP_053388845.1|	27.6	272	399	648	2.64e-15	76.6
C103_contig_117_633	NCBI|AJP12342.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	26.2	195	336	550	1.33e-09	58.2
C103_contig_117_639	SARG|gi|505420018|ref|WP_015607120.1|	31.8	242	250	603	9.58e-26	104
C103_contig_117_639	SARG|gi|695842130|ref|WP_032755430.1|	31.4	242	250	603	2.06e-24	100
C103_contig_117_639	SARG|gi|739906046|ref|WP_037756452.1|	31.6	228	250	620	9.73e-24	98.6
C103_contig_117_639	SARG|gi|516574297|ref|WP_017949361.1|	31.6	228	250	620	9.73e-24	98.6
C103_contig_117_639	SARG|gi|695865802|ref|WP_032778631.1|	30.2	242	250	605	1.10e-22	95.5
C103_contig_117_639	SARG|gi|817122037|ref|WP_046494699.1|	28.4	243	250	613	1.51e-22	95.1
C103_contig_117_639	SARG|gi|663350985|ref|WP_030349761.1|	28.5	242	250	613	2.04e-22	94.7
C103_contig_117_639	SARG|gi|947982677|ref|WP_056642336.1|	30.0	223	250	626	2.07e-22	94.7
C103_contig_117_639	SARG|gi|639892676|ref|WP_024755698.1|	30.0	223	250	631	2.08e-22	94.7
C103_contig_117_639	SARG|gi|639148059|ref|WP_024490169.1|	29.8	242	250	602	2.74e-22	94.4
C103_contig_117_659	SARG|gb|WP_104671188.1|ARO:3003948|efrA	43.5	538	721	575	2.27e-142	428
C103_contig_117_659	SARG|gb|AAK76137.1|ARO:3000024|patA	37.4	494	721	564	3.68e-108	339
C103_contig_117_659	SARG|gi|558888514|ref|WP_023543283.1|	31.4	493	721	615	4.37e-62	218
C103_contig_117_659	SARG|gi|1011969930|ref|WP_062776015.1|	30.0	530	721	601	1.68e-61	216
C103_contig_117_659	SARG|AF170880.4.gene1.p01	30.1	529	721	615	4.15e-61	215
C103_contig_117_659	SARG|gi|928900436|ref|WP_053931243.1|	30.5	492	721	600	4.33e-61	214
C103_contig_117_659	SARG|gi|664579989|ref|WP_031094015.1|	30.5	492	721	601	4.41e-61	214
C103_contig_117_659	SARG|gi|943938624|ref|WP_055567802.1|	30.4	530	721	602	8.55e-61	214
C103_contig_117_659	SARG|gb|CDO61516.1|ARO:3003949|efrB	36.9	347	721	362	4.42e-60	205
C103_contig_117_659	SARG|gi|943909899|ref|WP_055545300.1|	29.5	529	721	601	5.76e-60	211
C103_contig_117_660	SARG|gb|AAK76136.1|ARO:3000025|patB	39.2	577	616	588	1.78e-131	397
C103_contig_117_660	SARG|gb|CDO61516.1|ARO:3003949|efrB	50.7	341	616	362	2.58e-113	342
C103_contig_117_660	SARG|gb|AYV52072.1|ARO:3002882|lmrD	36.3	551	616	664	2.24e-108	339
C103_contig_117_660	SARG|gi|928900436|ref|WP_053931243.1|	31.2	587	616	600	2.91e-91	293
C103_contig_117_660	SARG|gi|664579989|ref|WP_031094015.1|	31.2	587	616	601	2.99e-91	293
C103_contig_117_660	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	32.4	586	616	579	1.82e-90	290
C103_contig_117_660	SARG|gi|517347347|ref|WP_018522839.1|	31.8	592	616	601	4.45e-90	290
C103_contig_117_660	SARG|AF170880.4.gene1.p01	31.3	578	616	615	8.83e-90	289
C103_contig_117_660	SARG|gi|496018010|ref|WP_008742581.1|	33.2	536	616	623	1.07e-89	289
C103_contig_117_660	SARG|gi|947982677|ref|WP_056642336.1|	31.4	586	616	626	1.16e-89	289
C103_contig_117_661	NCBI|CCA59315.1|1|1|helR|helR||1|rifamycin|rifamycin|RNA_polymerase_recycling_motor_ATPase_HelR|AMR|rifamycin	31.2	199	692	722	1.32e-19	92.4
C103_contig_117_685	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	40.4	218	239	255	7.66e-55	175
C103_contig_117_685	SARG|gi|446110305|ref|WP_000188160.1|	40.8	233	239	648	4.51e-51	174
C103_contig_117_685	SARG|Q83LR7	40.3	233	239	648	1.67e-50	173
C103_contig_117_685	SARG|gi|647325472|ref|WP_025760953.1|	40.3	233	239	648	1.67e-50	173
C103_contig_117_685	SARG|gi|647323678|ref|WP_025760497.1|	40.3	233	239	648	1.67e-50	173
C103_contig_117_685	SARG|gi|923061916|ref|WP_053445667.1|	40.1	232	239	648	2.32e-50	172
C103_contig_117_685	SARG|gi|555268037|ref|WP_023249477.1|	41.7	223	239	648	3.22e-50	172
C103_contig_117_685	SARG|gi|851902043|ref|WP_048212057.1|	39.3	234	239	648	3.22e-50	172
C103_contig_117_685	SARG|YP_002044935	40.1	232	239	648	4.47e-50	172
C103_contig_117_685	SARG|gi|835666879|ref|WP_047606339.1|	40.1	232	239	648	4.47e-50	172
C103_contig_117_687	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	24.8	804	884	1024	4.38e-70	250
C103_contig_117_687	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	24.8	804	884	1024	4.38e-70	250
C103_contig_117_687	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	24.8	804	884	1024	8.07e-70	249
C103_contig_117_687	SARG|gb|CAA53189|ARO:3000521|mupA	24.8	804	884	1024	8.07e-70	249
C103_contig_117_727	SARG|gi|851913025|ref|WP_048215946.1|	36.0	228	231	648	1.01e-37	137
C103_contig_117_727	SARG|gi|489930965|ref|WP_003834285.1|	36.0	228	231	648	1.01e-37	137
C103_contig_117_727	SARG|gi|936194420|ref|WP_054528571.1|	36.0	228	231	648	1.38e-37	137
C103_contig_117_727	SARG|gi|696368937|ref|WP_032943949.1|	36.1	227	231	648	1.38e-37	137
C103_contig_117_727	SARG|gi|851922185|ref|WP_048218206.1|	36.0	228	231	648	1.38e-37	137
C103_contig_117_727	SARG|YP_002850060	36.0	228	231	648	1.38e-37	137
C103_contig_117_727	SARG|gi|696375069|ref|WP_032949617.1|	36.0	228	231	648	1.38e-37	137
C103_contig_117_727	SARG|gi|489936909|ref|WP_003840216.1|	36.0	228	231	648	1.38e-37	137
C103_contig_117_727	SARG|gi|489127020|ref|WP_003036815.1|	36.0	228	231	648	1.38e-37	137
C103_contig_117_727	SARG|gi|507079862|ref|WP_016150620.1|	36.0	228	231	648	1.38e-37	137
C103_contig_117_741	NCBI|BAB64566.1|1|1|bexA|bexA|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_MATE_transporter_BexA|AMR|efflux	20.6	452	471	443	8.11e-21	93.6
C103_contig_117_746	SARG|gb|AAK76137.1|ARO:3000024|patA	26.3	205	351	564	1.17e-12	67.8
C103_contig_117_746	SARG|gb|AAK76136.1|ARO:3000025|patB	25.9	201	351	588	8.56e-09	55.8
C103_contig_117_746	SARG|gb|AYV52072.1|ARO:3002882|lmrD	24.2	219	351	664	4.50e-06	47.4
C103_contig_117_755	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	28.6	231	336	255	7.83e-26	102
C103_contig_117_755	SARG|gi|974633183|ref|WP_059219858.1|	32.4	241	336	648	1.91e-23	100
C103_contig_117_755	SARG|gi|446110269|ref|WP_000188124.1|	33.2	238	336	648	1.91e-23	100
C103_contig_117_755	SARG|YP_002328441	33.2	238	336	648	1.91e-23	100
C103_contig_117_755	SARG|gi|974684692|ref|WP_059267998.1|	32.4	241	336	648	1.91e-23	100
C103_contig_117_755	SARG|gi|643601187|ref|WP_025237288.1|	32.4	241	336	648	2.57e-23	99.8
C103_contig_117_755	SARG|gi|974628291|ref|WP_059215695.1|	32.4	241	336	648	2.57e-23	99.8
C103_contig_117_755	SARG|gi|446110298|ref|WP_000188153.1|	32.4	241	336	648	2.57e-23	99.8
C103_contig_117_755	SARG|gi|974672242|ref|WP_059256507.1|	32.4	241	336	648	3.47e-23	99.4
C103_contig_117_755	SARG|gi|446110308|ref|WP_000188163.1|	32.8	238	336	648	3.47e-23	99.4
C103_contig_117_756	SARG|gi|446048013|ref|WP_000125868.1|	30.4	240	337	648	2.83e-18	84.7
C103_contig_117_756	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	26.3	243	337	574	3.03e-15	75.5
C103_contig_117_759	SARG|gb|WP_104671188.1|ARO:3003948|efrA	41.2	548	578	575	2.87e-140	417
C103_contig_117_759	SARG|gb|AAK76137.1|ARO:3000024|patA	36.0	511	578	564	3.04e-100	314
C103_contig_117_759	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	29.4	585	578	579	2.61e-69	233
C103_contig_117_759	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	29.6	581	578	579	3.64e-69	233
C103_contig_117_759	SARG|gi|1045390184|ref|WP_065479071.1|	28.0	529	578	605	1.75e-64	221
C103_contig_117_759	SARG|gi|764446018|ref|WP_044369325.1|	28.2	529	578	605	2.43e-64	220
C103_contig_117_759	SARG|gb|ANZ79240.1|ARO:3004035|tetA(60)	28.2	581	578	579	2.81e-64	219
C103_contig_117_759	SARG|gi|928900436|ref|WP_053931243.1|	28.0	528	578	600	1.14e-63	218
C103_contig_117_759	SARG|gi|664579989|ref|WP_031094015.1|	28.0	528	578	601	1.17e-63	218
C103_contig_117_759	SARG|gi|951183771|ref|WP_057661487.1|	28.2	529	578	603	1.68e-63	218
C103_contig_117_760	SARG|gb|AYV52072.1|ARO:3002882|lmrD	36.1	532	581	664	1.16e-99	315
C103_contig_117_760	SARG|gb|AAK76136.1|ARO:3000025|patB	36.7	528	581	588	6.89e-99	311
C103_contig_117_760	SARG|gi|917203192|ref|WP_051809904.1|	32.5	572	581	620	1.01e-90	291
C103_contig_117_760	SARG|gi|917127754|ref|WP_051734466.1|	32.3	572	581	620	5.49e-90	289
C103_contig_117_760	SARG|gi|493394434|ref|WP_006350564.1|	31.8	573	581	602	6.93e-90	288
C103_contig_117_760	SARG|gi|926351744|ref|WP_053683383.1|	32.9	574	581	648	7.68e-90	289
C103_contig_117_760	SARG|gi|926376632|ref|WP_053705806.1|	32.2	572	581	620	1.51e-89	288
C103_contig_117_760	SARG|gi|799286378|ref|WP_045936958.1|	32.2	572	581	620	2.12e-89	287
C103_contig_117_760	SARG|gi|926294973|ref|WP_053631154.1|	32.2	572	581	620	2.12e-89	287
C103_contig_117_760	SARG|gi|926356413|ref|WP_053687351.1|	32.0	572	581	620	2.98e-89	287
C103_contig_117_764	NCBI|WP_038694170.1|1|1|dfrA49|dfrA49|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrA49|AMR|diaminopyrimidine	40.1	142	164	167	2.15e-27	99.8
C103_contig_117_764	SARG|gb|WP_197749399.1|ARO:3005349|DfrA38	41.5	135	164	166	5.19e-25	93.6
C103_contig_117_764	SARG|gb|WP_188331861.1|ARO:3005345|DfrA43_TMP	34.5	177	164	195	3.47e-17	73.9
C103_contig_117_764	SARG|gb|AAK64581.1|ARO:3004568|dfrA18	48.5	68	164	184	2.29e-08	50.1
C103_contig_117_792	SARG|gb|BAG33043.1|ARO:3003920|pgpB	29.7	148	186	236	1.85e-07	48.5
C103_contig_117_792	megares|MEG_5776|Drugs|Lipopeptide|Lipid_A_phosphatase|PGBB_1	29.7	148	186	236	1.85e-07	48.5
C103_contig_117_832	SARG|gi|515720450|ref|WP_017153050.1|	34.2	111	154	210	2.72e-11	58.2
C103_contig_117_832	SARG|AF155139.2.gene5.p01	34.3	108	154	206	3.59e-11	57.8
C103_contig_117_832	NCBI|WP_063856927.1|1|1|vanZ-Pt|vanZ-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_protein_VanZ-Pt|AMR|glycopeptide	35.5	110	154	159	4.91e-11	56.6
C103_contig_117_832	SARG|gi|1028848471|ref|WP_064017434.1|	32.7	110	154	206	9.56e-11	56.6
C103_contig_117_832	SARG|gi|670466162|ref|WP_031414939.1|	32.4	108	154	206	2.53e-10	55.5
C103_contig_117_840	SARG|AAN28721	47.3	74	398	108	1.58e-16	73.9
C103_contig_117_876	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	33.7	315	314	343	1.60e-57	187
C103_contig_117_876	megares|MEG_4276|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|OLEC_1	30.1	309	314	325	1.02e-45	156
C103_contig_117_876	SARG|gb|AAA26793|ARO:3003748|oleC	30.0	307	314	325	2.83e-45	155
C103_contig_117_876	SARG|gi|542061059|gb|ERI11611.1|	37.3	225	314	316	1.33e-43	150
C103_contig_117_876	SARG|YP_001373621	30.1	309	314	318	3.52e-39	139
C103_contig_117_876	SARG|P42332	28.8	316	314	306	8.17e-37	132
C103_contig_117_876	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	28.0	314	314	306	1.14e-36	132
C103_contig_117_876	SARG|gi|510143239|gb|AGN36970.1|	28.0	314	314	313	1.33e-36	132
C103_contig_117_876	SARG|AAD21213	28.8	316	314	306	3.13e-36	131
C103_contig_117_876	SARG|ABB80128	28.2	312	314	306	4.37e-36	130
C103_contig_117_878	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	30.4	102	207	228	4.48e-07	47.8
C103_contig_117_918	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	39.9	692	642	703	1.05e-140	425
C103_contig_117_953	SARG|HE999704.1.gene3064.p01	28.9	197	447	241	8.54e-12	63.9
C103_contig_117_953	SARG|gi|441475675|emb|CCQ25429.1|	33.9	127	447	211	3.80e-10	58.5
C103_contig_117_953	SARG|gb|BAD89844.2|ARO:3000753|abeM	23.0	456	447	448	7.17e-10	59.7
C103_contig_117_955	SARG|gi|446048013|ref|WP_000125868.1|	27.5	222	514	648	8.97e-19	88.6
C103_contig_117_955	SARG|gb|AYV52072.1|ARO:3002882|lmrD	28.3	212	514	664	1.25e-13	72.4
C103_contig_117_973	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	35.4	209	284	307	4.48e-34	124
C103_contig_117_973	NCBI|QHA94808.1|1|1|narA|narA||1|MADURAMICIN/NARASIN/SALINOMYCIN|IONOPHORE|ionophore_ABC_transporter_ATP-binding_subunit_NarA|AMR|ionophore	33.3	210	284	293	1.94e-31	117
C103_contig_117_973	SARG|gi|445996710|ref|WP_000074565.1|	33.6	232	284	309	2.01e-29	112
C103_contig_117_973	SARG|gi|542061059|gb|ERI11611.1|	33.0	209	284	316	2.29e-29	112
C103_contig_117_973	SARG|gi|895736250|emb|COF64653.1|	33.2	232	284	309	7.57e-29	110
C103_contig_117_973	SARG|gi|446110087|ref|WP_000187942.1|	33.2	232	284	309	7.57e-29	110
C103_contig_117_973	SARG|gi|445996719|ref|WP_000074574.1|	32.7	217	284	309	1.05e-28	110
C103_contig_117_973	SARG|gi|445996714|ref|WP_000074569.1|	33.2	232	284	309	1.05e-28	110
C103_contig_117_973	SARG|gi|814314593|emb|CKF49145.1|	33.2	232	284	309	1.47e-28	110
C103_contig_117_973	SARG|gi|895808656|emb|COR83787.1|	32.8	232	284	309	2.84e-28	109
C103_contig_117_982	NCBI|WP_005480402.1|1|1|tet(35)|tet(35)|efflux|2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_Na+/H+_antiporter_family_transporter_Tet(35)|AMR|tetracycline	38.7	524	541	533	1.35e-106	328
C103_contig_117_982	SARG|AF353562.gene.p01	37.8	341	541	369	1.52e-60	203
C103_contig_117_1004	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	38.4	219	224	228	1.26e-42	142
C103_contig_117_1004	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	36.6	224	224	231	3.84e-42	141
C103_contig_117_1004	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	37.5	224	224	232	1.24e-40	137
C103_contig_117_1004	CARD|gb|ATC67679.1|ARO:3000838|arlR	33.5	221	224	219	2.73e-39	134
C103_contig_117_1004	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.5	217	224	219	5.43e-39	133
C103_contig_117_1004	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.5	217	224	219	7.66e-39	132
C103_contig_117_1004	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.5	217	224	220	7.87e-39	132
C103_contig_117_1004	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.5	217	224	220	1.11e-38	132
C103_contig_117_1004	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	32.9	228	224	231	3.61e-36	126
C103_contig_117_1004	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	32.9	228	224	231	5.09e-36	125
C103_contig_117_1005	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	26.4	250	348	359	2.41e-18	84.0
C103_contig_117_1005	CARD|gb|AEX49906.1|ARO:3003583|basS	23.8	235	348	477	3.60e-17	81.3
C103_contig_117_1005	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	25.2	246	348	364	4.72e-15	74.3
C103_contig_117_1005	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	25.2	246	348	364	4.72e-15	74.3
C103_contig_117_1066	SARG|DQ212986.1.gene3.p01	41.4	70	91	75	6.11e-16	65.1
C103_contig_137_corr_5_np12_36	SARG|gi|445996708|ref|WP_000074563.1|	37.2	207	292	309	1.56e-33	123
C103_contig_137_corr_5_np12_36	SARG|gi|488120365|ref|WP_002191762.1|	36.2	224	292	309	3.05e-33	122
C103_contig_137_corr_5_np12_36	SARG|gi|445996709|ref|WP_000074564.1|	36.3	226	292	309	3.05e-33	122
C103_contig_137_corr_5_np12_36	SARG|gi|507050365|ref|WP_016121371.1|	35.7	224	292	309	3.05e-33	122
C103_contig_137_corr_5_np12_36	SARG|gi|507055561|ref|WP_016126482.1|	36.4	209	292	309	3.05e-33	122
C103_contig_137_corr_5_np12_36	SARG|gi|488053456|ref|WP_002124853.1|	36.4	209	292	309	4.26e-33	122
C103_contig_137_corr_5_np12_36	SARG|gi|488067981|ref|WP_002139378.1|	36.4	209	292	309	8.32e-33	121
C103_contig_137_corr_5_np12_36	SARG|gi|487936534|ref|WP_002010000.1|	36.4	209	292	309	8.32e-33	121
C103_contig_137_corr_5_np12_36	SARG|gi|488068784|ref|WP_002140181.1|	36.8	209	292	309	8.32e-33	121
C103_contig_137_corr_5_np12_36	SARG|gi|447057510|ref|WP_001134766.1|	36.4	209	292	309	1.16e-32	121
C103_contig_137_corr_5_np12_43	CARD|gb|ATC67679.1|ARO:3000838|arlR	38.1	218	225	219	4.52e-44	146
C103_contig_137_corr_5_np12_43	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	39.9	228	225	231	3.55e-43	144
C103_contig_137_corr_5_np12_43	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	36.3	223	225	228	7.28e-42	140
C103_contig_137_corr_5_np12_43	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	37.2	223	225	232	3.22e-41	139
C103_contig_137_corr_5_np12_43	NCBI|WP_063856722.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	36.5	230	225	232	6.41e-41	138
C103_contig_137_corr_5_np12_43	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	34.9	232	225	235	5.48e-40	136
C103_contig_137_corr_5_np12_43	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	36.8	228	225	231	1.09e-38	132
C103_contig_137_corr_5_np12_43	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	36.4	228	225	231	1.53e-38	132
C103_contig_137_corr_5_np12_43	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	34.8	230	225	233	1.62e-38	132
C103_contig_137_corr_5_np12_43	NCBI|WP_063856715.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	36.5	230	225	232	2.22e-38	132
C103_contig_137_corr_5_np12_66	SARG|YP_001373621	43.5	223	389	318	1.30e-48	166
C103_contig_137_corr_5_np12_66	SARG|gi|447195835|ref|WP_001273091.1|	44.3	212	389	306	3.70e-48	164
C103_contig_137_corr_5_np12_66	SARG|gi|507055561|ref|WP_016126482.1|	42.8	222	389	309	3.99e-48	164
C103_contig_137_corr_5_np12_66	SARG|gi|488053456|ref|WP_002124853.1|	42.8	222	389	309	3.99e-48	164
C103_contig_137_corr_5_np12_66	SARG|gi|488068784|ref|WP_002140181.1|	42.8	222	389	309	3.99e-48	164
C103_contig_137_corr_5_np12_66	SARG|gi|447057509|ref|WP_001134765.1|	42.3	222	389	309	7.85e-48	164
C103_contig_137_corr_5_np12_66	SARG|ZP_04081918	43.9	212	389	306	1.02e-47	163
C103_contig_137_corr_5_np12_66	SARG|gi|447195836|ref|WP_001273092.1|	43.9	212	389	306	1.02e-47	163
C103_contig_137_corr_5_np12_66	SARG|gi|445996719|ref|WP_000074574.1|	42.3	222	389	309	1.10e-47	163
C103_contig_137_corr_5_np12_66	SARG|gi|488067981|ref|WP_002139378.1|	42.3	222	389	309	1.10e-47	163
C103_contig_137_corr_5_np12_80	SARG|gb|ANZ79476.1|ARO:3003908|Erm(47)	34.8	187	292	246	5.50e-23	94.0
C103_contig_137_corr_5_np12_80	SARG|gb|QQM99828.1|ARO:3007041|Erm(52)	31.4	188	292	309	7.57e-21	89.4
C103_contig_137_corr_5_np12_80	SARG|L22689.1.gene1.p01	28.3	244	292	257	5.66e-18	80.5
C103_contig_137_corr_5_np12_80	NCBI|WP_052259183.1|1|1|erm(42)|erm(42)|target_modification|2|CLINDAMYCIN/ERYTHROMYCIN|LINCOSAMIDE/MACROLIDE|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(42)|AMR|multidrug	29.9	184	292	301	5.95e-16	75.5
C103_contig_137_corr_5_np12_80	megares|MEG_2781|Drugs|MLS|23S_rRNA_methyltransferases|ERM42_1	29.9	184	292	303	6.07e-16	75.5
C103_contig_137_corr_5_np12_80	SARG|gb|CBY77552.1|ARO:3003106|Erm(42)	29.9	184	292	301	1.11e-15	74.7
C103_contig_137_corr_5_np12_88	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	26.6	271	383	370	1.13e-28	114
C103_contig_137_corr_5_np12_88	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	25.1	271	383	365	1.25e-26	108
C103_contig_137_corr_5_np12_88	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	26.7	307	383	359	3.01e-23	98.6
C103_contig_137_corr_5_np12_88	SARG|gb|AAG05187.1|ARO:3005067|ParS	27.5	258	383	428	9.43e-19	86.3
C103_contig_137_corr_5_np12_88	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	27.6	214	383	364	9.11e-18	82.8
C103_contig_137_corr_5_np12_88	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	27.6	214	383	364	9.11e-18	82.8
C103_contig_137_corr_5_np12_88	CARD|gb|AEX49906.1|ARO:3003583|basS	25.0	300	383	477	2.96e-17	82.0
C103_contig_137_corr_5_np12_89	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	43.8	224	230	231	1.21e-64	199
C103_contig_137_corr_5_np12_89	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	43.7	229	230	232	7.13e-64	197
C103_contig_137_corr_5_np12_89	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	43.7	229	230	232	7.13e-64	197
C103_contig_137_corr_5_np12_89	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	44.9	225	230	232	6.57e-62	192
C103_contig_137_corr_5_np12_89	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	43.6	225	230	233	1.10e-60	189
C103_contig_137_corr_5_np12_89	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	41.3	230	230	239	2.41e-58	183
C103_contig_137_corr_5_np12_89	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	40.8	228	230	231	1.08e-57	181
C103_contig_137_corr_5_np12_89	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	40.8	228	230	231	1.08e-57	181
C103_contig_137_corr_5_np12_89	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	40.5	227	230	231	4.32e-57	180
C103_contig_137_corr_5_np12_89	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	39.6	225	230	229	5.76e-57	179
C103_contig_137_corr_5_np12_96	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	45.1	679	641	703	1.71e-175	514
C103_contig_137_corr_5_np12_158	SARG|gb|AAK76137.1|ARO:3000024|patA	30.4	217	247	564	5.61e-18	81.6
C103_contig_137_corr_5_np12_196	SARG|ABB80128	28.0	236	513	306	1.19e-16	79.7
C103_contig_137_corr_5_np12_196	SARG|gi|445996719|ref|WP_000074574.1|	28.9	242	513	309	1.23e-16	79.7
C103_contig_137_corr_5_np12_196	SARG|gi|445996710|ref|WP_000074565.1|	27.9	219	513	309	2.23e-16	79.0
C103_contig_137_corr_5_np12_196	SARG|gi|445996722|ref|WP_000074577.1|	28.9	242	513	309	2.23e-16	79.0
C103_contig_137_corr_5_np12_196	SARG|gi|884875933|emb|CKG93789.1|	28.9	242	513	309	3.00e-16	78.6
C103_contig_137_corr_5_np12_196	SARG|gi|445996723|ref|WP_000074578.1|	28.5	242	513	309	3.00e-16	78.6
C103_contig_137_corr_5_np12_196	SARG|gi|895808656|emb|COR83787.1|	28.3	233	513	309	3.00e-16	78.6
C103_contig_137_corr_5_np12_196	SARG|P42332	28.8	233	513	306	3.90e-16	78.2
C103_contig_137_corr_5_np12_196	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	28.8	233	513	306	3.90e-16	78.2
C103_contig_137_corr_5_np12_196	SARG|gi|445996724|ref|WP_000074579.1|	28.9	242	513	309	4.04e-16	78.2
C103_contig_137_corr_5_np12_225	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	41.9	105	822	231	2.71e-15	75.1
C103_contig_137_corr_5_np12_225	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	39.7	121	822	232	3.73e-15	74.7
C103_contig_137_corr_5_np12_225	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	30.1	153	822	231	2.78e-12	66.2
C103_contig_137_corr_5_np12_225	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	32.5	114	822	231	2.16e-08	54.7
C103_contig_137_corr_5_np12_225	NCBI|XSG12259.1|1|1|drcR|drcR||1|||daptomycin_efflux_response_regulator_transcription_factor_DrcR|AMR|peptide	27.5	120	822	223	2.64e-08	54.3
C103_contig_137_corr_5_np12_225	CARD|gb|ADM92605.1|ARO:3000553|adeR	25.9	158	822	247	1.51e-07	52.4
C103_contig_137_corr_5_np12_225	CARD|gb|AAD51348.1|ARO:3003066|smeR	30.6	121	822	229	4.07e-07	50.8
C103_contig_137_corr_5_np12_264	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	30.6	232	323	255	3.20e-26	103
C103_contig_137_corr_5_np12_264	SARG|gi|639216333|ref|WP_024554080.1|	31.2	234	323	648	7.38e-25	103
C103_contig_137_corr_5_np12_264	SARG|gi|896325272|ref|WP_049294291.1|	30.8	234	323	648	2.46e-24	102
C103_contig_137_corr_5_np12_264	SARG|gi|657888313|ref|WP_029592374.1|	31.2	234	323	648	4.49e-24	101
C103_contig_137_corr_5_np12_264	SARG|gi|639225329|ref|WP_024561799.1|	30.8	234	323	648	2.02e-23	99.8
C103_contig_137_corr_5_np12_264	SARG|gi|639218559|ref|WP_024556062.1|	30.8	234	323	648	2.02e-23	99.8
C103_contig_137_corr_5_np12_264	SARG|gi|974588181|ref|WP_059178476.1|	29.1	234	323	646	2.72e-23	99.4
C103_contig_137_corr_5_np12_264	SARG|YP_001176128	29.5	234	323	646	3.67e-23	99.0
C103_contig_137_corr_5_np12_264	SARG|gi|556487375|ref|WP_023335108.1|	30.1	236	323	646	4.95e-23	98.6
C103_contig_137_corr_5_np12_264	SARG|gi|981224618|ref|WP_059445588.1|	30.1	236	323	646	4.95e-23	98.6
C103_contig_137_corr_5_np12_265	SARG|gi|446048013|ref|WP_000125868.1|	29.8	208	329	648	4.23e-19	87.0
C103_contig_137_corr_5_np12_265	NCBI|WP_289811734.1|1|1|tetA(60)|tetA(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_A|AMR|tetracycline	27.8	237	329	579	2.48e-17	81.6
C103_contig_137_corr_5_np12_265	SARG|gb|ANZ79240.1|ARO:3004035|tetA(60)	29.3	215	329	579	2.48e-17	81.6
C103_contig_137_corr_5_np12_266	SARG|gb|CAE00499.1|ARO:3003835|cdeA	23.3	438	582	441	7.98e-30	121
C103_contig_137_corr_5_np12_266	SARG|gi|313638554|gb|EFS03703.1|	23.9	427	582	453	2.09e-17	84.0
C103_contig_137_corr_5_np12_266	SARG|gi|984518628|emb|CUM21384.1|	27.0	285	582	341	1.22e-16	80.5
C103_contig_137_corr_5_np12_266	SARG|gi|313614636|gb|EFR88215.1|	24.0	425	582	453	3.63e-16	80.1
C103_contig_137_corr_5_np12_266	SARG|gi|313609598|gb|EFR85124.1|	25.8	225	582	226	1.17e-15	75.5
C103_contig_137_corr_5_np12_266	SARG|gi|313619623|gb|EFR91268.1|	25.8	221	582	237	1.77e-13	69.3
C103_contig_137_corr_5_np12_267	NCBI|WP_252944138.1|1|1|almE|almE||2|COLISTIN|COLISTIN|lipid_A_modification_system_glycine--protein_ligase_AlmE|AMR|peptide	26.7	509	2997	556	3.66e-37	149
C103_contig_137_corr_5_np12_282	NCBI|WP_109545033.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	27.8	270	332	355	2.28e-22	95.1
C103_contig_137_corr_5_np12_282	megares|MEG_7602|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	27.8	270	332	355	2.28e-22	95.1
C103_contig_137_corr_5_np12_282	SARG|ACM47285	27.8	270	332	363	2.50e-22	95.1
C103_contig_137_corr_5_np12_282	megares|MEG_7603|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	28.6	248	332	355	4.28e-22	94.4
C103_contig_137_corr_5_np12_282	SARG|BAE96115	28.6	248	332	355	4.28e-22	94.4
C103_contig_137_corr_5_np12_282	megares|MEG_7604|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_2	29.0	186	332	209	1.29e-15	73.6
C103_contig_137_corr_5_np12_283	CARD|gb|ATC67679.1|ARO:3000838|arlR	31.5	108	238	219	4.45e-07	48.1
